Coordinating Gene Therapies of Cystic Fibrosis Airway Disease with Anti-Inflammatory and Antimicrobial Cationic Glucocorticoids by Myint, Melissa
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2015
Coordinating Gene Therapies of Cystic Fibrosis
Airway Disease with Anti-Inflammatory and
Antimicrobial Cationic Glucocorticoids
Melissa Myint
University of Pennsylvania, melissa.myint@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Biomedical Commons, and the Chemical Engineering Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1101
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Myint, Melissa, "Coordinating Gene Therapies of Cystic Fibrosis Airway Disease with Anti-Inflammatory and Antimicrobial Cationic
Glucocorticoids" (2015). Publicly Accessible Penn Dissertations. 1101.
http://repository.upenn.edu/edissertations/1101
Coordinating Gene Therapies of Cystic Fibrosis Airway Disease with Anti-
Inflammatory and Antimicrobial Cationic Glucocorticoids
Abstract
Certain sterol-based cationic lipids demonstrate both anti-inflammatory and antimicrobial characteristics in
addition to their abilities to facilitate gene transfer. These characteristics are particularly suited for enhancing
potential gene therapies of cystic fibrosis (CF) airway disease, a condition characterized by chronic infections
and concomitant inflammation. Unfortunately, however, animal models of CF do not show the airway disease
typically seen in humans, so in vivo efficacies of potential therapies are difficult to assess. In this work, three
mouse models were established to evaluate adeno-associated virus (AAV) gene transfer in an infected airway
environment. Bordetella bronchiseptica RB50 was used in a chronic, non-lethal respiratory infection model
with C57BL/6 mice. Administration of an AAV vector on day 2 of this infection resulted in an approximate
three-fold reduction of reporter gene expression, compared to that observed in uninfected controls.
Postponement of AAV administration to day 14 resulted in an even greater (eight-fold) reduction in gene
expression. Separately, Pseudomonas aeruginosa PAO1 was used to infect surfactant protein D or surfactant
protein A knockout mice to establish acute infections. Reporter gene expression was approximately ~2.5-fold
lower in these infected mice than in uninfected mice, when AAV was administered on day 2 of infection.
Interestingly, when AAV administration was postponed to day 9 of infection in the surfactant protein D
knockout model, partial regain in expression was observed. In this case, infection resulted in only a two-fold
(vs ~2.5-fold) reduction in gene expression. To reverse these negative effects on gene transfer, six new sterol-
based cationic lipids were synthesized and characterized. Of the six lipids tested, two, budesonide spermine
and disubstituted budesonide spermine, showed particularly promising in vitro activities and were used to
establish proof-of-concept efficacy in an acute infection model. PAO1-infected mice received lipids on day 1
of infection and AAV 24 hours later on day 2. When reporter gene expression was measured one week later,
only a ~1.5-1.9-fold reduction in gene expression, compared to the ~2.7-fold reduction seen with untreated
controls. Results demonstrate that treatment with dual functioning anti-inflammatory, antimicrobial cationic
glucocorticoids can be coordinated with CF gene therapies to restore loss of transduction efficiency caused by
active infection.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Chemical and Biomolecular Engineering
First Advisor
Scott L. Diamond
Keywords
Cationic Glucocorticoids, Cystic Fibrosis, Gene Therapy
This dissertation is available at ScholarlyCommons: http://repository.upenn.edu/edissertations/1101
Subject Categories
Biomedical | Chemical Engineering
This dissertation is available at ScholarlyCommons: http://repository.upenn.edu/edissertations/1101
COORDINATING GENE THERAPIES OF CYSTIC FIBROSIS AIRWAY 
DISEASE WITH ANTI-INFLAMMATORY AND ANTIMICROBIAL 
CATIONIC GLUCOCORTICOIDS 
Melissa Myint 
A DISSERTATION 
in 
Chemical and Biomolecular Engineering 
Presented to the Faculties of the University of Pennsylvania 
in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy 
2015 
 
Supervisor of Dissertation       
____________________________     
Scott L. Diamond      
Professor, Chemical and Biomolecular Engineering 
        
Graduate Group Chairperson 
____________________________ 
Raymond J. Gorte 
Professor, Chemical and Biomolecular Engineering 
 
Dissertation Committee  
Daniel A. Hammer, Professor, Department of Chemical and Biomolecular Engineering 
Matthew J. Lazzara, Assistant Professor, Department of Chemical and Biomolecular Engineering  
James M. Wilson, Professor, Department of Pathology and Laboratory Medicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
COORDINATING GENE THERAPIES OF CYSTIC FIBROSIS AIRWAY DISEASE 
WITH ANTI-INFLAMMATORY AND ANTIMICROBIAL  
CATIONIC GLUCOCORTICOIDS 
 
COPYRIGHT 
 
2015 
 
Melissa Myint
 
  
iii 
 
ACKNOWLEDGMENTS 
 The work represented here in these pages would not have been possible without the support 
and guidance of so many of my colleagues, friends, and family.  First and foremost, I want to thank 
my advisor, Scott Diamond, without whom I would not be the ambitious and resilient researcher I am 
today. His direction and management style has led me to accomplishments and success that cannot be 
valued in ordinary words, and I will be forever grateful for the opportunities he has made available to 
me. I would also like to thank the other members of my committee, Dr. Dan Hammer, Dr. Matt 
Lazzara, and Dr. Jim Wilson, whose challenging questions at my proposal helped me to think 
critically about my work and the real-world value that I had to offer through it.   
I must also thank the members of the Diamond Lab, past and present, whose company and 
support over the years has been invaluable. Special thanks goes to David Fein, who, despite having 
graduated several years before I joined the lab, did not shy away from training me over the phone 
during my first year. The countless hour-long conversations filled with so many gems of wit, wisdom, 
and scientific enthusiasm carried me through my project in its earliest years when nothing seemed to 
quite go my way. I will be forever grateful for the time and effort he invested in me and my success. 
To all others in my lab who were not directly involved in my project, particularly Viraj Kamat, Mei 
Yan Lee, Brad Herbig, Dr. Andrew Dolan, Dr. Joel Outten, and our wonderful and dedicated  lab 
manager, Jing Huiyan, your company and support over the years have made working in the Diamond 
lab a truly enjoyable and memorable experience.  
To my closest scientific collaborators outside of the Diamond Lab, Robert Bucki and Maria 
Limberis, words cannot express how invaluable your mentorship and scientific guidance have been. 
Robert, our impromptu conversations in the hallways of the IME always led to interesting and 
provoking thought streams on the applications and future directions of my work. Maria, your high 
standards and expectations for my scientific caliber were, at first, incredibly intimidating, but because 
of them, I stand taller and much less unafraid to embrace the unknown. Your advisory style has taught 
iv 
 
me to push beyond the limits of my current capacities in order to provide scientific answers in the 
most thorough and efficient manner possible. To others in the Wilson lab who have impacted this 
work, Marco Crosariol, Christine Draper, and Deirdre McMenimin, thank you for being so very 
helpful and such delightful company alongside difficult and challenging animal work. You made TRL 
my second home on campus, and I am immensely grateful for having collaborators with such 
accommodating and open arms.  
Thanks must also be extended to others in my life not directly involved in this research: 
Marvin Jackson in the IME and my fellow CBE classmate, Sarah Stapleton. Marvin, your presence in 
the IME was essential to my sanity over the years – thank you for your professional and efficient 
management of the IME administrative tasks, but more importantly, for the countless mid-day chats or 
last-minute check ins at Mad Mex after work.  Your words of encouragement and moments of much 
need comic relief were essential to my time here. Sarah, you were a defining star of my adventures 
here at Penn, despite having only spent a portion of it together in Philly. I would not have been able to 
achieve as much as I have without your unconditional support and sound advice over the years. The 
delicious meals and vital cups of coffee that we shared during your time here proved pretty helpful as 
well.  
Finally, I must extend immense thanks and gratitude to my family for always being so 
supportive. Ricky and Steph, thank you for always being there and providing an unjudging haven 
whenever I needed to come home and rejuvenate my intellectual ambitions. To Mom and Dad, thank 
you for all the sacrifices you have made to provide me with the best education possible. Because of 
you, I was able to build myself a world full of endless opportunities and potential for my future. And 
lastly, to Mark Walker, you have been the truest of true friends, the people that we choose to be 
family.  I am eternally grateful for all of the support, patience, and inspiration you have granted me 
during my time here. I simply would not have been able to do this without you. Thank you for 
everything you have done to push me to be the very best version of myself.  
  
v 
 
ABSTRACT 
COORDINATING GENE THERAPIES OF CYSTIC FIBROSIS AIRWAY DISEASE 
WITH ANTI-INFLAMMATORY AND ANTIMICROBIAL  
CATIONIC GLUCOCORTICOIDS 
Melissa Myint 
Scott L. Diamond 
 
Certain sterol-based cationic lipids demonstrate both anti-inflammatory and antimicrobial 
characteristics in addition to their abilities to facilitate gene transfer. These characteristics are 
particularly suited for enhancing potential gene therapies of cystic fibrosis (CF) airway disease, a 
condition characterized by chronic infections and concomitant inflammation. Unfortunately, 
however, animal models of CF do not show the airway disease typically seen in humans, so in 
vivo efficacies of potential therapies are difficult to assess. In this work, three mouse models were 
established to evaluate adeno-associated virus (AAV) gene transfer in an infected airway 
environment. Bordetella bronchiseptica RB50 was used in a chronic, non-lethal respiratory 
infection model with C57BL/6 mice. Administration of an AAV vector on day 2 of this infection 
resulted in an approximate three-fold reduction of reporter gene expression, compared to that 
observed in uninfected controls. Postponement of AAV administration to day 14 resulted in an 
even greater (eight-fold) reduction in gene expression. Separately, Pseudomonas aeruginosa 
PAO1 was used to infect surfactant protein D or surfactant protein A knockout mice to establish 
acute infections. Reporter gene expression was approximately ~2.5-fold lower in these infected 
mice than in uninfected mice, when AAV was administered on day 2 of infection. Interestingly, 
when AAV administration was postponed to day 9 of infection in the surfactant protein D 
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knockout model, partial regain in expression was observed. In this case, infection resulted in only 
a two-fold (vs ~2.5-fold) reduction in gene expression. To reverse these negative effects on gene 
transfer, six new sterol-based cationic lipids were synthesized and characterized. Of the six lipids 
tested, two, budesonide spermine and disubstituted budesonide spermine, showed particularly 
promising in vitro activities and were used to establish proof-of-concept efficacy in an acute 
infection model. PAO1-infected mice received lipids on day 1 of infection and AAV 24 hours 
later on day 2. When reporter gene expression was measured one week later, only a ~1.5-1.9-fold 
reduction in gene expression, compared to the ~2.7-fold reduction seen with untreated controls. 
Results demonstrate that treatment with dual functioning anti-inflammatory, antimicrobial 
cationic glucocorticoids can be coordinated with CF gene therapies to restore loss of transduction 
efficiency caused by active infection. 
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1.0  Introduction 
1.1 Cystic Fibrosis 
Cystic fibrosis is the most common lethal genetic disorder amongst Caucasians, affecting 
approximately 1 in every 2000 people [1]. The disease is a caused by a single defective gene, 
specifically a mutated CFTR, which encodes for the cystic fibrosis transmembrane conductance 
regulator (CFTR). The CFTR is a transmembrane protein channel that is responsible for 
regulating liquid volumes at epithelial surfaces by transporting anions, namely chloride and 
bicarbonate anions, across the cell membrane as necessary. In individuals with CF, this protein is 
either missing or defective, resulting in osmotic imbalances that produce an unusually thick and 
extremely viscous mucus layer at epithelial surfaces (Figure 1.1) [2–4]. 
 
Figure 1.1: A depiction of a normal and mutant CFTR protein channel. 
Adapted from [5]. Without proper transport of anions, osmotic forces cause a thick and viscous mucus to build up at the 
outer cell surface. 
 
 
Clinical symptoms of this condition arise in several different areas of the body, including 
the pancreas, intestines, and reproductive organs. The most serious complications, however, 
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present in the upper and lower airways (Figure 1.2). Progressive respiratory disease causes 95% 
of all CF mortalities [6]. Due to conditions of their disease, CF patients are particularly 
susceptible to chronic infections by a pathogen, Pseudomonas aeruginosa. By the age of 17, 
nearly 70% of CF patients are infected with this opportunistic bacterium, and once acquired, P. 
aeruginosa is difficult to completely eradicate from the CF airway. Nearly 80% of CF adults have 
chronic P. aeruginosa infections that cannot be eliminated by antibiotic therapy [7]. The 
persisting infection results in ongoing inflammation and pulmonary complications that can be 
ultimately lethal [8].  
 
Figure 1.2: A schematic comparison of a normal and CF airway.  
CF airways are characterized by narrowed and inflamed airways, which are congested with a thick and viscous mucus.  
 
1.2 Gene Therapy for Cystic Fibrosis 
Gene therapy is the use of nucleic acids to treat or prevent disease. It offers a promising 
therapeutic option for many genetic disorders, particularly those caused by a single defective 
gene, like CF. In such instances,  restorative function depends on the successful delivery and 
expression of only a single gene [9]. Additionally, CF airway disease is especially suited for 
treatment by gene therapy due to the ease of accessibility of the target organ and the minimal 5-
10% of normal CFTR expression necessary to correct the phenotype [10]. However, over 20 years 
has elapsed since the discovery of the CFTR gene, and still, no viable genetic treatment option 
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exists for curing or alleviating CF airway disease. Major barriers, both physical and 
immunological, exist as obstacles for successful gene transfer.  
1.3 Barriers to Successful Pulmonary Gene Delivery and Expression  
1.3.1 Extracellular Barriers 
 As a major interface with the external environment, the lungs and conducting airways 
have evolved efficient physical barriers by which to prevent penetration of any unwanted foreign 
particles and substances. One such barrier, mucociliary clearance, is made possible by a ciliated 
epithelium bathed in biphasic layer of airway fluid secretions [11,12]. The cilia are situated in the 
aqueous (“sol”) layer, also known as the periciliary layer, where they beat and relax. Above the 
sol layer sits a mucus (“gel”) layer composed of high molecular weight glycoproteins, known as 
mucins, linked to lipids and proteins. The physical, i.e. viscoelastic and adhesive, properties of 
this gel layer allow it to trap inhaled particles, while the beating the underlying cilia facilitate 
upward movement for removal of these unwanted substances. Other physical barriers against 
foreign particles include a glycocalyx that can prevent gene carriers (or vectors) from binding to 
appropriate cell receptors and a general scarcity of these receptors on the apical side of the 
epithelium [13].  
 Sophisticated innate and adaptive immune mechanisms of the respiratory tract also play a 
role in preventing successful gene transfer in the airway. Alveolar macrophages eliminate gene 
carriers or products either directly by phagocytosis or indirectly by their abilities to recruit other 
immune cells as antigen-presenting cells [14]. Other immune cells, e.g. neutrophils, dendritic 
cells, and lymphocytes, also can play a role in preventing successful gene transfer in the airway. 
These cells are responsible for initiating and facilitating non-specific inflammation as well as 
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cellular and humoral immune responses that can target the gene carriers and/or the gene products 
themselves.  
1.3.2 Intracellular Barriers 
Once past the extracellular barriers, genes carriers must then overcome additional 
obstacles at the intracellular level. These vectors must be able to penetrate the cell membrane, 
either by non-specific or receptor-mediated mechanisms. Typically these mechanisms involve 
endocytic pathways facilitated by clathrin-coated pits, lipid rafts, and/or direct fusion with the 
membrane [15].  In any case, vectors are typically internalized into endosomes, from which they 
must then escape before acidic changes in pH initiate the lysosomal degradation pathway [16].  
Unfortunately, additional barriers exist even after endosomal release. Once in the cytosol, vectors 
must be able to migrate to the nucleus and penetrate the nuclear membrane for entry, all while 
avoiding additional opportunities for degradation by nucleases within the cytoplasm before 
reaching this final destination [17]. 
1.4 Overcoming Barriers to Gene Transfer  
Multiple approaches are available to overcome these barriers to effective gene transfer.  
The correct choices in gene vector as well as in any pre- or co-treatments with chemical 
enhancers can allow desired genes to more easily by bypass host immune responses or physical 
barriers preventing proper delivery. Viral vectors are efficient and effective at transferring their 
genetic material to desired cell types but tend to be much more immunogenic than their nonviral 
alternatives. However, while easy to use and manufacture, nonviral gene carriers are unable to 
achieve the efficiencies associated with viral gene carriers. Efforts are ongoing to address the 
drawbacks of each type of vector.  
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1.4.1 Cationic Lipids as Chemical Enhancers of Gene Therapy Vectors 
 One such effort involves the use of cationic lipids, which are able to facilitate delivery of 
DNA to cells. Addition of these lipids to DNA forms complexes, known as lipoplexes, that 
exhibit lower overall negative charge and easier associations with cellular membranes than 
standalone, or naked, DNA is able to. These physiochemical changes allow lipoplexes to shield 
DNA from extra- and intracellular nucleases by compacting its size and concealing it within its 
lipid bilayers [18]. Neutral lipids, such as cholesterol or dioleoylphosphatidylethanolamine 
(DOPE), can be included to aid in the formation of liposomal structures [16]. DOPE is 
particularly useful due to its ability to fuse with other lipids at low pH, e.g. in an endosome 
preparing to initiate lysosomal degradation. By fusing with lipids at this stage in endosomal 
processing, DOPE can facilitate release of the DNA before degradation begins [19]. Additionally, 
cationic lipids can enhance performance of viral vectors as well. Incubation with cationic 
liposomes increases the gene expression efficiency, reduces the associated immunogenicity, 
and/or modifies the tropism of certain viral vectors [20–22].  
1.5 Cationic Glucocorticoids for Improving Gene Therapies of CF 
 One particular category of cationic lipid has particular promise for enhancing gene 
therapies of CF, namely lipids that are spermine-based cationic glucocorticoids. Two such 
compounds, dexamethasone spermine (DS) and disubstituted dexamethasone spermine (D2S) 
(Figure 1.3), were previously developed by this lab and shown to have both anti-inflammatory 
and antimicrobial characteristics [23,24]. This dual functionality is particularly suited for 
applications in CF, a disease characterized by on-going inflammation and chronic infections with 
opportunistic bacteria. Dual acting cationic lipids, like DS, D2S, and similarly structured cationic 
glucocorticoids, could be used to facilitate better gene transfer of gene therapy vectors while also 
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treating the infection and hyperinflammatory environment so commonly encountered in CF 
patients.  
 
Figure 1.3: Chemical structures of DS and D2S 
1.5 Current Research Goals  
DS and D2S showed promising pharmacological activity in vitro, but the in vivo efficacy 
of these compounds had not been verified at the start of this work. While seemingly simple in 
theory to execute, this task was difficult to accomplish due to the lack of a relevant and 
convenient animal model in which to test potential therapeutics for CF. Mice that have been 
engineered to lack the CFTR gene do not show the airway disease typically seen in CF humans 
[25]. Furthermore, P. aeruginosa, the bacterium responsible for most chronic infections in CF 
patients, is not a naturally infectious pathogen of murine animals. If the bacteria are not first 
embedded in an artificial biofilm (i.e. embedded in beads composed of agar, agarose, or seaweed 
alginate) before administration to the animal, a lasting infection is unachievable [26]. 
Administration of free bacteria results in either rapid clearance of the organism or acute sepsis 
and death [27]. 
1.5.1 Specific Aim 1: Mouse Models of Infection for In Vivo Evaluation of Airway Gene Transfer 
Consequently, the first objective of this work was to establish non-invasive and 
reproducible in vivo models of airway infection to test potential therapies relevant for CF airway 
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disease. Separately, the models presented here incorporate different aspects of clinical 
presentations of CF airway disease. Methods for one model establishes a chronic airway infection 
with a natural murine pathogen, while methods for the other two models establish infections that 
are more acute in nature but utilize P. aeruginosa in a physiological environment relevant for CF.  
1.5.2 Specific Aim 2: Structure-activity Relationships of Novel Cationic Glucocorticoids   
The second objective of this work was to investigate structure-activity relationships of 
similarly structured cationic glucocorticoids. DS and D2S, while potent in vitro, may not be the 
most ideal choices for practical applications in treating CF airway disease. Preliminary studies on 
the effects of D2S in rat models of arthritis demonstrated significant systemic activity of the lipid 
in the body [28]. While local anti-inflammatory (i.e. immunosuppressive) activity is a desirable 
trait for potential CF treatments, compounds with strong systemic activity could be ultimately 
lethal during situations involving active infections. Thus, ideal therapeutic candidates are 
compounds with potent local effects but limited systemic consequences. In this work, six new 
cationic glucocorticoids were synthesized and characterized to further understanding of how this 
family of compounds can be modified accordingly to achieve such desired characteristics.  
1.5.3 Specific Aim 3: In Vivo Evaluation of Coordinated Gene Therapies with Anti-inflammatory 
and Antimicrobial Cationic Glucocorticoids during Active Airway Infections   
Ultimately, the goal of this work is to coordinate gene therapies with these dual 
functioning cationic glucocorticoids and validate these methods as treatments for CF airway 
disease. The final objective of this work was to test these coordinated therapies in the animal 
models established as part of Specific Aim 1.  Two of the novel cationic glucocorticoids 
developed in Specific Aim 2 showed particularly promising in vitro potency and were used to 
establish proof-of-concept efficacy in vivo.  
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2.0  In vivo evaluation of adeno-associated virus gene transfer in 
airways of mice with acute or chronic respiratory infection 
2.1 Abstract 
 
While gene therapy development for CF often involves viral-based vectors, little is 
known about gene transfer in the context of an infected airway. In this study, three mouse models 
were established to evaluate adeno-associated virus (AAV) gene transfer in such an environment. 
Bordetella bronchiseptica RB50 was used in a chronic, non-lethal respiratory infection in 
C57BL/6 mice. An inoculum of ~10
5 
CFU allowed B.bronchiseptica RB50 to persist in the upper 
and lower respiratory tracts for at least 21 days. In this infection model administration of an AAV 
vector on day 2 resulted in an approximately three-fold reduction of reporter gene expression 
compared to that observed in uninfected controls. Postponement of AAV administration to day 14 
resulted in an even greater (eight-fold) reduction of reporter gene expression, when compared to 
uninfected controls. In another infection model Pseudomonas aeruginosa PAO1 was used to 
infect surfactant protein D (SP-D) or surfactant protein A (SP-A) knockout (KO) mice. With an 
inoculum of ~10
5 
CFU, infection persisted for two days in the nasal cavity of either mouse model. 
Reporter gene expression was approximately ~2.5 fold lower compared to uninfected mice. In the 
SP-D KO model, postponement of AAV administration to day 9 post-infection resulted in only a 
2-fold reduction in reporter gene expression, when compared to expression seen in uninfected 
controls. These results confirm that respiratory infections, both on-going and recently resolved, 
decrease the efficacy of AAV-mediated gene transfer.   
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2.2 Introduction 
 
Deterioration of the lung in CF patients is due to a cycle of infection by opportunistic 
pathogens and neutrophilic inflammation [29]. By the age of 17, nearly 70% of CF patients have 
P. aeruginosa in their sputum at levels of 10
6
-10
8
 CFU/gr sputum [30], and approximately 80% 
of adult CF patients are chronically infected with P. aeruginosa that cannot be eliminated by 
antibiotic therapy [7]. In a Phase II gene therapy trial with AAV-CFTR, nearly 70% of CF 
patients receiving the AAV2 vector were P. aeruginosa colonized [31]. The presence of infection 
was an endpoint of measurement in the trial and was not a basis for exclusion from the trial. 
Separately, a Phase IIB trial with AAV2-CFTR that included three doses of 10
13
 particles 
administered 30 days apart failed to demonstrate efficacy [32]. In this clinical trial of 102 CF 
subjects, the number of days of antibiotic use was considered a marker for trial monitoring. 
Infection in CF airways is expected during the progress of the gene therapy regimen, and about 
15% of CF subjects were on antibiotics while they received aerosolized AAV2 for this study. In a 
clinical trial of interferon gamma-1b with 66 CF patients, sputum bacterial density was 7.1 Log10 
CFU/gr with 80 to 90% of enrolled subjects having P. aeruginosa infection [33]. The sickest CF 
patients have chronic lung infection but the presence of P. aeruginosa in sputum has not been a 
criterion for exclusion in airway-directed gene therapy clinical trials. The failure of CF AAV 
gene therapy trials may be due in part to the difficulty of gene delivery to lungs that sustain and 
harbor a chronic disease state due to infection. Little research, however, has been done to 
investigate the effects of microbial infection on airway gene transfer.  
The paucity of research in this area may be related to the lack of a relevant animal model 
necessary to study such effects. Current methods are laborious and introduce issues of mechanical 
and physical damage that are not naturally seen with clinical presentations of CF.  This study 
presents three alternatives for studying gene transfer in an infected airway that are reproducible 
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and non-invasive. The first involves a natural murine pathogen, Bordetella bronchiseptica (Bb) 
RB50, to establish a chronic infection in C57BL/6 mice. Bb infects a number of members of the 
mammalian family, and in rodents, rabbits, cats, dogs, and pigs, it typically establishes an 
asymptomatic infection in the nasal cavity that persists indefinitely [34,35]. In the lower 
respiratory tract, the infection is enduring, but transient, with the bacterial load reducing to almost 
baseline within 45 days [35]. The second and third scenarios utilize P. aeruginosa PAO1 to 
establish an acute infection in surfactant protein D (SP-D) and surfactant protein A (SP-A) 
knockout mice, respectively. SP-D and SP-A  are pulmonary collectins that are important in 
innate immunity against various bacterial and viral pathogens [36]. Decreased or lack  of SP-D 
and SP-A has been implicated in the pathogenesis of CF airway disease [37]. When knockout 
mice were engineered to lack either SP-D or SP-A, they were found to have decreased ability to 
effectively clear P. aeruginosa [38]. The resulting infection was still transient lasting only a few 
days, but the resulting inflammatory response was exaggerated when compared to WT mice. As 
hyperinflammatory responses are also typical of CF patients, the SP-D and SP-A KO mice 
emulate key inflammatory aspects of the disease when compared to WT mice.  
In this report, we employed these mouse models to study adeno-associated virus (AAV)-
mediated gene transfer in infected airways. Figure 2.1 depicts the experimental design used. The 
presence of an on-going or even recently resolved infection decreased AAV-mediated gene 
transfer efficiency in the airway, validating the use of these models to optimize gene transfer for 
relevant airway diseases like CF.  
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Figure 2.1: A schematic of experimental design. 
Mice are i.n. infected with freshly cultured bacteria on day 0. On day 2, 9, or 14, an AAV9 vector containing a ffluc 
reporter gene is introduced to the recently infected airway via intranasal instillation. Three to four randomly selected 
mice are also taken on the day of AAV administration for evaluation of bacterial load and characterization of immune 
response at the time of vector administration (n=3 for uninfected controls, n=4 for infected groups). Approximately 
every week thereafter, the remaining mice are dosed with luciferin and subjected to live imaging to evaluate ffluc 
expression. Abbreviations: AAV, adeno-associated virus; IN, intranasal; ffluc, firefly luciferase; NLF, nasal lavage 
fluid; BALF, bronchoalveolar lavage fluid. 
2.3 Materials and Methods 
 
2.3.1 Bacterial Strains and Growth Conditions 
B. bordetella strain RB50 was a kind gift from Dr. Yasuhiko Irie, University of 
Washington, Seattle, WA. Bb was cultured in Stainer-Scholte (SS) broth or on Bendet Gengou 
(BG) blood agar (BD Diagnostic Systems, Sparks, MD) at 37°C. P. aeruginosa PAO1 was a kind 
gift from Dr. Robert Bucki, University of Pennsylvania, Philadelphia, PA. The bacterium was 
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cultured at 37°C in Miller’s Lysogeny Broth (LB) (Mediatech, Herndon, VA) or on Pseudosel™ 
Agar (cetrimide agar) from BD Diagnostic Systems.  
2.3.2 AAV Preparation 
The AAV9 vectors flanked with AAV2 inverted terminal repeats (ITRs) contained a 
firefly luciferase (ffluc) reporter gene fused to a nucleus localization sequence at the N-terminus 
under the transcriptional control of the cytomegalovirus (CMV)-enhanced chicken-β-actin 
promoter. Vectors were produced by the Penn Vector core as previously described [39].  
2.3.3 Mice 
C57BL/6 male mice were purchased from Charles River Laboratories (Wilmington, MA), 
while SP-D and SP-A knockout mice [40] were maintained in-house at the University of 
Pennsylvania.  Mice were age-matched and used between 7 and 14 weeks of age. For all 
experiments, a group size of at least 3 mice was used for each experimental cohort. All animals 
were maintained at the Animal Facility of the Translation Research Laboratories at the University 
of Pennsylvania under protocols reviewed and approved by the University of Pennsylvania’s 
Institutional Animal Care and Use Committee. Prior to all intranasal administrations, mice were 
anesthetized by an intraperitoneal injection of ketamine/xylazine (70/7 mg/kg) and were 
subsequently suspended from their dorsal incisors (hind quarters supported) for dosing. 
2.3.4 Preparation of Inoculum 
Bacteria were grown overnight in their appropriate liquid media at 37°C with shaking at 
250 rpm. Approximately 16-18 hours later, the bacteria were diluted into fresh broth to an optical 
density (λ=600nm) reading of 0.1 and were allowed to grow until mid-logarithmic phase (optical 
density at λ=600nm of ~0.5 for Bb RB50 and ~0.4 for P. aeruginosa). At that point, the bacteria 
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were harvested and washed once in phosphate-buffered saline (PBS) before being diluted into 
fresh PBS at the desired concentration (controlled by evaluation of optical density at 600 nm).  
2.3.5 Mouse Infection Model for Evaluation of Airway Transduction 
Before challenge, mice were anesthetized intraperitoneally and suspended from their 
dorsal incisors, as described earlier. Mice were then intranasally (i.n.) challenged with a 30-µL 
bolus (delivered as two 15 µL aliquots, one into each nostril) of Bb RB50 or P. aeruginosa PAO1 
to achieve approximately 10
5 
CFU/mouse. At specified time points later (i.e. 2, 9, or 14 days after 
infection), mice were i.n. administered 5 × 10
10
 genome copies (GC) of AAV vector in 20-µL (10 
µL into each nostril).  
To evaluate ffluc expression, mice (~20 grams) were anesthetized and suspended before 
20 µL of D-luciferin (15 mg/mL) was i.n. administered as two 10 µL aliquots, one into each 
nostril. After 5 minutes, mice were imaged for 60 seconds with the IVIS Xenogen imaging 
system. Quantification of signal was calculated with the Living Image 2.5.1 software.  
2.3.6 Evaluation of Bacterial Load 
To determine bacterial load, three samples were taken from each randomly selected 
mouse: (a) lungs, (b) bronchoalveolar lavage fluid (BALF), and (c) nasal lavage fluid (NLF). 
Before the lungs were harvested, BALF was collected by instilling 500 µL of sterile PBS through 
a cannula into the trachea. Fluid was collected and re-instilled into the lungs for a total of three 
times before being collected into a 1.5-mL tube. The lungs (~110-150mg per lung) were then 
excised. One lung was inflated with a 1:1 mixture of Tissue Tek® OCT and PBS, embedded in 
OCT in a storage cassette and flash frozen with cooled 2-methylbutane. Frozen lungs were kept at 
-80°C until further histological processing. The other lung was homogenized in 1.5 mL of sterile 
PBS for evaluation of bacterial load. For the NLF samples, mice were decapitated and a cannula 
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attached to a 1-mL syringe containing 300 µL of sterile PBS was placed into the tracheal 
remnant. PBS was then flushed through the nasal passages and collected through the nares into a 
1.5-mL tube. This recovered fluid was used to flush the nasal cavity another two times, for a total 
of three flushes. All samples were kept on ice until further processing. 
To determine the CFU counts in each sample, solutions were diluted 10-, 100-, and 1000-
fold. Ten-microliter aliquots of each dilution were spotted in duplicate on the appropriate solid 
selection agar for each bacterial strain (BG blood agar for Bb and Pseudosel™ agar for P. 
aeruginosa). Plates were incubated at 37°C for 48 hours for Bb RB50 and 16 hours for P. 
aeruginosa. The number of colonies at each dilution was then counted, and the concentration of 
CFU of each sample was back calculated from the dilution factor.  
2.3.6 BALF Cell Analysis 
Cytospin slides were prepared using 50 µL of freshly isolated BALF diluted into 100 µL 
of fresh PBS. After centrifugation (Shandon Cytospin 3, Thermo Fisher Scientific Inc., Waltham, 
MA) for 5 minutes at 1,000 rpm, cells were allowed to air dry for 10 minutes. Cells were then 
fixed with 10% neutral buffered formalin, washed in PBS, stained with Nuclear Fast Red (Sigma 
Aldrich, St. Louis, MO), dehydrated with a series of ethanols, and cleared with xylene according 
to standard protocols. Cells were studied and characterized using light microscopy (IX81; 
Olympus America Inc., Center Valley, PA).  
2.3.7 Lung Immunohistochemistry 
Immunofluorescence staining was performed on frozen lung sections. Sections were 
fixed in acetone at -20ºC for 7 min, air dried, blocked in 1% donkey serum in PBS for 20 min, 
and incubated with primary rat antibodies diluted in blocking buffer against CD8 (clone 53-6.7, 
BD Biosciences; 1:20), CD4 (clone RM4-5, BD Biosciences; 1:20), and Mac-2 (clone M3/38, 
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Cedarlane; 1:200) for 45 min. After washing in PBS sections were stained with secondary donkey 
antibodies labeled with FITC or TRITC (Jackson Immunoresearch Laboratories) for 30 min, 
washed in PBS, and mounted in Vectashield containing DAPI (Vector Laboratories). For 
detection of neutrophils, cryosections were fixed in 4% paraformaldehyde in PBS for 10 min. 
Sections were then permeabilized and blocked in 0.2% Triton containing 1% donkey serum for 
30 min and stained with a rabbit antibody against myeloperoxidase (Abcam) followed by 
secondary antibodies and washing steps as described above.  
2.3.8 BALF Cytokine Analysis 
A multiplex bead assay based on the Luminex technology was used to measure 
cytokine/chemokine levels in BALF samples that were collected from mice as described earlier. 
A 25-panel multi-analyte cytokine/chemokine kit (Millipore, MA) was used according to the 
manufacturer’s instructions. Briefly, 25 μL of samples were incubated overnight at 4°C with 
capture beads against G-CSF, GM-CSF, IFN-γ, TNF-α, RANTES, IL-1α, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α, 
MIP-1β, and MIP-2 on a rocking platform. The following day beads were washed using a hand 
held magnetic block (Millipore, MA) and stained with biotin antibodies at room temperature for 
one hour. The beads were further stained for 30 min using streptavidin detection antibodies 
before a series of final washes. Beads were read on a Luminex 200 instrument (Luminex, TX) 
and levels determined by regressing against a 7-point standard curve (Bioplex Manager, Biorad).  
2.3.9 Statistical Analysis 
Statistical analysis was performed using Microsoft Office Excel 2007 (Microsoft, 
Redmond, WA). The Student’s t-Test was used to determine significance of differences between 
two groups.  
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2.4 Results 
To evaluate the effects of a chronic bacterial infection on gene transfer in the airway, 
C57BL/6 mice were i.n. challenged with approximately 10
5 
CFU of Bb RB50 or sterile PBS. 
Mice were tested for evidence of infection through day 21 post-infection, and in all RB50-
infected mice, bacteria were detected at significant levels (10
4
-10
7 
CFU) in both the nasal cavity 
and lung throughout the duration of the study (Figure 2.2A). All samples from mice receiving 
only sterile PBS showed no evidence of RB50 at all time points tested (data not shown). On day 2 
or day 14 of infection, mice were given an intranasal dose of AAV9.ffluc. One week after AAV 
administration, mice were subjected to live whole animal luminescent imaging. At both time 
points, the luminescent signal in the nasal cavity of the infected mice was significantly lower 
(P<0.01, Student’s t-Test) than that observed in the nasal cavity of the uninfected mice (Figure 
2.2, B and C). It is worthwhile to note that the loss in expression was greater (eightfold, Figure 
2.2C) when AAV administration was delayed to day 14 of infection. The significant difference in 
ffluc expression in the nasal cavity between uninfected mice and infected mice receiving AAV on 
day 14 was sustained for 50 days after AAV delivery (Figure 2.3). 
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Figure 2.2: Effects of a sustained RB50 airway infection on AAV9-mediated transduction in C57BL/6 mice. 
(A) RB50 colonization of C57BL/6 mouse airway. Approximately 105 CFU of bacteria were delivered i.n. in 30 µL. 
Bacterial colonization was analyzed through harvest of lungs, BALF, and NLF from three to four randomly selected 
mice at specified time points over the course of 21 days. The plots show means ± standard deviations for n=4-11 mice 
tested at each time point in four different experiments. Samples taken from uninfected mice were clear of RB50 at all 
time points. Dashed line denotes detection limit. Abbreviations: BALF, bronchoalveolar lavage fluid; NLF, nasal 
lavage fluid. (B and C) AAV9-mediated transduction in wild-type C57BL/6 mice recently infected with RB50.  Two  
or fourteen days after receiving intranasal inoculations of either sterile PBS or ca. 105 CFU of B. bronchiseptica, mice 
were i.n. dosed with AAV9.ffluc. Mice were later assessed for gene expression one week later: (B) mice that received 
AAV on day 2 of infection and (C) mice that received AAV on day 14 of infection. Plots show quantification of 
luminescence from mouse nasal cavity. Results are presented as means, and error bars represent the standard deviation 
for the six mice imaged at each time point. Significantly lower signal was observed from the nasal cavities of infected 
mice (**P < 0.01, Student’s t-Test, n=6). 
18 
 
 
Figure 2.3: Long-term AAV9 gene expression in nasal cavities of C57BL/6 mice previously infected with RB50. 
Animals were transduced with AAV9.ffluc on day 14 of a Bb infection and imaged for ffluc expression every week 
until day 86 post-AAV administration. Bb-infected mice show significantly lower nasal cavity luminescence than that 
observed from uninfected controls through day 50 (**P<0.01, *P<0.05, Student’s t-test, n=6 at day 7, n=3 for all other 
time points).  PBS, AAV9,   Bb, AAV9. 
 
To determine whether a transient acute infection would have a similar effect, P. 
aeruginosa PAO1 was used to infect SP-D knockout mice. Mice were i.n. challenged with 
approximately 10
5
 CFU of PAO1 and control mice given sterile PBS. On day 2 or day 9 post-
infection, a representative sampling of mice (uninfected n=3, infected n=4) was taken to 
determine the status of the infection in the lungs and nose at the time of AAV administration 
(Figure 2.4, A and B). Samples from uninfected mice showed no evidence of PAO1 at both time 
points tested (data not shown). On day 2, PAO1 was only found in the nasal cavity at relatively 
low levels (~80 CFU). Lung and BALF samples isolated from the lower respiratory tract showed 
no evidence of infection. By day 9, the majority of mice had cleared the bacteria from their 
airways. However, despite the limited presence of bacteria in the nasal cavity, ffluc expression 
was still significantly lower (P<0.01, Student’s t-Test) in the noses of infected mice in both cases 
(Figure 2.4, D and E). Consistent observations were seen at subsequent time points through to day 
14 post-transduction (Figure 2.5,A-B).  
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Figure 2.4: Effects of a transient P. aeruginosa PAO1 airway infection on AAV9-mediated transduction in SP-D 
or SP-A KO mice. 
(Top, A-C) PAO1 colonization of SP-D or SP-A KO mouse airway. Approximately 105 CFU of bacteria were delivered 
i.n. in 30 µL. Bacterial colonization was analyzed through harvest of lungs, BALF, and NLF from three or four 
randomly selected mice at specified time points: (A) SP-D KO mice at day 2 post-infection, (B) in SP-D KO mice at 
day 9 post-infection, and (C) in SP-A KO mice at day 2 after infection. Plots show means ± standard deviations for 
n=5-7 mice tested at each time point in three different experiments for SP-D KO mice and n=3 mice from a single 
experiment for SP-A KO mice. Samples taken concurrently from uninfected mice were clear of PAO1 at all time points 
tested. Abbreviations: BALF, bronchoalveolar lavage fluid; NLF, nasal lavage fluid. (Bottom, D-F) AAV9-mediated 
transduction in SP-D or SP-A KO mice recently infected with PAO1. Two or nine days after being challenged with 
sterile PBS or approximately 105 CFU of P. aeruginosa PAO1, mice were i.n. dosed with AAV9.ffluc. One week later, 
mice were imaged for gene expression: (D) SP-D KO mice that received AAV on day 2 of infection, (E) SP-D KO 
mice that received AAV on day 9 of infection, and (F) SP-A KO mice that received AAV on day 2 of infection. Plots 
show quantification of luminescence from mouse nasal cavity. Results are presented as means, and error bars represent 
the standard deviation for the mice imaged at each time point. Significantly lower signal was observed from the nasal 
cavities of infected mice (**P < 0.01, *P < 0.05, Student’s t-Test, uninfected n=6, infected SP-D KO mice receiving 
AAV on Day 2 n=11, infected mice SP-D KO receiving AAV on Day 9 n=8, n=7 for both SP-A KO mice groups). 
 
To determine whether infection would have similar effects on gene expression in mice 
lacking SP-A, the SP-A KO mice were i.n. challenged with ~10
5
 CFU of PAO1 or sterile PBS. 
On day 2 post-infection, mice (uninfected n=3, infected n=4) were peeled to mice determine the 
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status of infection in the SP-A nasal and lung airways at the time of AAV administration (Figure 
2.4C). As observed in the SP-D KO mice, bacteria were only found in the nasal cavity at 
relatively low levels (~80 CFU) on day 2 post-infection, and samples from uninfected mice 
showed no evidence of PAO1 (data not shown). Additionally, similar trends on reporter gene 
expression were also observed; ffluc expression was significantly lower (P<0.05, Student’s t-Test) 
in the nasal cavity of infected mice (Figure 2.4F). Consistent observations were seen at 
subsequent time points through day 21 post-transduction (Figure 2.5C).  
 
Figure 2.5: Long-term AAV9 gene expression in nasal cavities of SP-D or SP-A KO mice previously infected 
with PAO1. 
(A) SP-D KO mice transduced on day 2 of infection. (B) SP-D KO mice transduced on day 9 of infection. (C) SP-A 
KO mice transduced on day 2 of infection. Mice were imaged every week until the specified day post-AAV 
administration. PAO1-infected mice show significantly lower nasal cavity luminescence than that observed from 
uninfected mice through the first two time points in each experiment (**P<0.01, *P<0.05, Student’s t-Test, for (A): 
Day 7 uninfected n=6, Day 7 infected n=10, for all other time points uninfected n =3 and infected =6; for (B): Day 7 
uninfected n=6, Day 7 infected n=8, for all other time points uninfected n =3 and infected=4; for (C): Day 7 uninfected 
n=7, Day 7 infected n=7, for all other time points: uninfected n=3 and infected n=4 ).   PBS, AAV9,   PAO1, 
AAV9. 
 
The immune response at the time of AAV administration was then characterized to 
provide insights into the observed mechanisms. Cytology on fresh BALF samples indicated that 
actively infected mice were characterized by substantial neutrophil infiltration on day 2 of 
infection (Figures 2.6R, 2.7R, 2.8J). Samples from uninfected mice only showed evidence of 
alveolar macrophages (Figures 2.6Q, 2.7Q, 2.8I). Interestingly, uninfected SP-D KO mice had a 
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small number of neutrophils in their BALF samples in addition to macrophages that were 
characterized by a foamy and/or multi-nucleated appearance (Figure 2.7Q). By day 9 post-PAO1 
infection, many of the neutrophils had band, rather than segmented, nuclei (Figure 2.7T), 
indicative of a shift towards immature precursors.  
Histology on frozen lung sections showed similar trends (Figures 2.6-2.8). Day 2 of 
infection was characterized by significant neutrophil and macrophage infiltration for the Bb 
chronic infection and the PAO1 acute infection in the SP-A KO model (Figures 2.6 and 2.8, E-H). 
Day 2 of infection was also characterized by an elevated CD8 T cell population in the SP-A KO / 
PAO1 model (Figure 2.8G). Interestingly, in the SP-D KO / PAO1 acute infection model, 
neutrophils and macrophages were present in the lungs of uninfected mice (Figure 2.7, A and B). 
We also observed small numbers of CD8 T cells in the uninfected lung and these increased 
slightly with infection. By day 9 post-infection with PAO1, lung samples from the SP-D KO mice 
showed little to no differences between uninfected and infected groups for all cell types detected 
(Figure 2.7N).  Day 14 of Bb infection in C57BL/6 mice, on the other hand, was characterized by 
elevated neutrophil and macrophage populations (Figure 2.6, M and N). Additionally, day 14 
samples from infected lungs also showed a larger presence of CD4 T cells but not CD8 T cells 
(Figure 2.6, O and P).    
Analysis of cytokine/chemokine levels in BALF samples isolated from a representative 
sampling of mice (typically uninfected n=3, infected n=4) at the time of AAV administration 
demonstrated the most notable differences on day 2 of infection for all infection models (Figure 
2.9). Of the 25 analytes measured, nine of them (GM-CSF, IL-2, IL-4, IL-5, IL-7, IL-9, IL-12p40, 
IL-13 and IL-15) showed no differences between groups in any of the infection models used in 
this study (data not shown). The remaining 16 (G-CSF, IFN-γ, IL-1α, IL-1β, IL-6, IL-10, IL-
12p70, IL-17, IP-10, KC, MCP-1, MIP-1γ, MIP-1β, MIP-2, TNF-α, and RANTES) displayed 
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substantial differences between uninfected  and infected groups on day 2 post-infection in at least 
one of the infection models tested (Figure 2.9). Determination of statistical significance for 
differences observed in the SP-A KO / PAO1 model was limited by the number of samples 
available for analysis (n=2 for each group). At the later time points tested, i.e. at day 14 after Bb 
infection and at day 9 after PAO1 infection, many of the elevated analytes (i.e., G-CSF, IFN-γ, 
IL-1β, IL-6, IL-10, IL-12p70, IP-10, MCP-1, and MIP-1γ) returned to baseline. The remaining 
analytes, IL-1α, IL-17, KC, MIP-1β, MIP-2, TNF-α, and RANTES, were still elevated in samples 
obtained from Bb-infected mice. In the SP-D KO / PAO1 model, all cytokines and chemokines 
levels had returned to baseline by day 9 post-infection.  
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Figure 2.6: Characterization of immune response at time of AAV administration in Bb chronic infection model. 
(A-P), Lung histology of C57BL/6 mice transduced at specified time points during Bb airway infection. Lungs were 
harvested on the day of AAV administration and sectioned and stained with antibodies against antigens for the 
specified cell type. Representative images are shown here: sections from (A-D) uninfected mice on day 2, (E-H) 
infected mice on day 2, (I-L) uninfected mice on day 14, and (M-P) infected mice on day 14. Notable neutrophil and 
macrophage infiltration was observed in samples from infected lungs. Day 9 showed an elevated CD4 T cell population 
as well. Arrows indicate evidence of elevated cell populations. Magnification, x 20. (Q-T) Cytospin preparations of 
cells recovered from fresh BALF samples taken on day of AAV administration: (Q,S) samples taken from uninfected 
mice on day 2 and day 14, respectively, (R,T) samples taken from infected mice on day 2 and day 14, respectively. 
Representative macrophages (Ma) and neutrophils (Ne) are indicated in the figure. Samples from uninfected mice 
showed only macrophages, while samples from infected mice showed a prominent neutrophil presence in addition to 
the macrophage cell population at both time points.  
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Figure 2.7: Characterization of immune response at time of AAV administration in SP-D KO / PAO1 acute 
infection model. 
(A-P), Lung histology of SP-D KO mice transduced at specified time points during PAO1 airway infection. Lungs were 
harvested on the day of AAV administration and sectioned and stained with antibodies against antigens for the 
specified cell type. Representative images are shown here: sections from (A-D) uninfected mice on day 2, (E-H) 
infected mice on day 2, (I-L) uninfected mice on day 9, and (M-P) infected mice on day 9. Day 2 samples from 
uninfected mice displayed evidence of neutrophils, macrophages, and CD8 T cells. Infected samples at this time point 
showed slightly elevated levels of the same cell types, as indicated by the arrows. By day 9, only macrophages remain 
slightly elevated.  Magnification, x 20. (Q-T) Cytospin preparations of cells recovered from fresh BALF samples taken 
on day of AAV administration:  (Q,S) samples taken from uninfected mice on day 2 and day 9, respectively, (R,T) 
samples taken from infected mice on day 2 and day 9, respectively. Representative macrophages (Ma), neutrophils 
(Ne), and band neutrophils (band Ne) are indicated in the figure. Day 2 samples from uninfected mice showed 
macrophages and a small neutrophilic presence. Infected samples at this same time point displayed a much larger 
neutrophils population. By day 9, both macrophages and neutrophils were still seen. However, neutrophils on day 9 had 
band (instead of segmented) nuclei, indicative a shift towards immature precursors. 
  
25 
 
 
Figure 2.8: Characterization of immune response at time of AAV administration in SP-A KO / PAO1 acute 
infection model. 
 (A-H), Lung histology of SP-A KO mice transduced on day 2 during PAO1 airway infection. Lungs were harvested on 
the day of AAV administration and sectioned and stained with antibodies against antigens for the specified cell type. 
Representative images are shown here: sections from (A-D) uninfected mice and (E-H) infected mice. On day 2, 
elevated levels of neutrophils, macrophages, and CD8 T cells were evident in samples from infected lungs (see arrows). 
Magnification, x 20. (I-J) Cytospin preparations of cells recovered from fresh BALF samples taken on day of AAV 
administration: (I) samples taken from uninfected mice and (J) samples taken from infected mice. Representative 
macrophages (Ma) and neutrophils (Ne) are indicated in the figure. Samples from uninfected mice showed only 
macrophages, while infected samples showed obvious neutrophil infiltration in addition to the macrophage cell 
population. 
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Figure 2.9: BALF cytokine/chemokine levels at time of AAV administration.  
Cytokine/chemokine levels were determined using a Milliplex 25-plex premixed magnetic mouse cytokine/chemokine 
array and Luminex bead reader according to the manufacturer’s instructions. Single asterisk (*) indicates samples that 
exceeded the upper limit of detection of the assay, approximately 10,000 pg/mL. Results are presented as means, and 
error bars represent the standard deviation (··P<0.01, ·P<0.05, Student’s t-Test, uninfected n=2-5, infected n=3-7 for all 
groups except SP-A KO infected mice where n=2 for both uninfected and infected mice). 
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2.5 Discussion 
 
CF airway disease remains an ideal candidate for treatment by gene therapy, despite its 
limited success seen so far. Individuals with CF are characterized by chronic respiratory 
infections that are primarily responsible for the high morbidity and early mortality rates 
associated with the disease. However, limited research has been done to determine the effects of 
active airway infections on pulmonary gene transfer. The lack of research on this topic is not 
surprising as no convenient animal model exists to study such effects. Three different mouse 
models were established in this study to remedy this issue. The first involved creating a chronic 
infection in C57BL/6 mice with a natural murine pathogen, B. bronchiseptica RB50. The second 
and third models utilized PAO1 to establish an acute, but persistent, infection in SP-D and, 
separately, SP-A KO mice, respectively.  
When an AAV vector was administered to the airways of infected mice on day 2 post-
infection, transduction efficiency was similarly reduced in all mouse models, despite remarkable 
differences in the duration and intensity of all infection models. The approximate 3-fold reduction 
in gene expression was seen regardless of several additional factors, including the bacterium 
used, the strain of mouse used, or the bacterial load at the time of AAV administration. This 
suggests that immune response at the time of vector administration was the main cause for the 
observed reduction in gene transfer efficiency.  
Characterization of these immune responses at day 2 of infection showed that the 
responses in each infection model were generally similar to each other. Analyses showed that day 
2 inflammatory responses were dominated by macrophage and neutrophil infiltration, the latter of 
which is characteristic of the infected CF lung [29]. However, in the SP-D KO / PAO1 acute 
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infection model, elevated levels of macrophages and neutrophils were present even in uninfected 
lung samples, suggesting that their presence alone is insufficient to reduce  gene transfer.  
While immune responses at day 2 were generally similar between all infection models 
studied, one striking difference observed was between the chronic and transient acute infection 
models. In the SP-D and SP-A KO / PAO1 infection models, CD8 T cell activation/recruitment 
was observed in the infected lungs. In the lungs of Bb-infected mice, the numbers of CD8 T cells 
were not elevated compared to uninfected mice. Despite this apparent difference, we observed a 
similar level of reduction in gene expression in all three infection models, suggesting that CD8 T 
cells are not directly involved in the reduction of gene transfer.  
When AAV administration was delayed to a later time point post-infection, different 
effects on AAV-mediated gene expression were seen between the Bb chronic infection and the 
SP-D KO / PAO1 acute infection models. In the Bb chronic infection model, postponement of 
AAV administration to day 14 post-infection resulted in a significant (8-fold, P<0.01, Student’s t-
Test) reduction in gene expression when compared to the expression seen in uninfected controls. 
In the SP-D KO / PAO1 acute infection model, however, delay of AAV administration to day 9 
post-infection resulted in a ~2-fold reduction. The notable differences observed in the immune 
response at these time points include: (1) elevated levels of macrophages, segmented neutrophils, 
and CD4 T cells in Bb-infected mice but not in PAO1-infected mice and (2) elevated levels of IL-
1α, IL-17, KC, MIP-1β, MIP-2, TNF-α, and RANTES in Bb-infected mice but not PAO1-infected 
mice. While PAO1-infected SP-D mice did display elevated levels of neutrophils in their BALF 
samples, many of these cells showed a band, rather than a segmented, nucleus, indicative of 
immature neutrophilic precursors. Taken together, these results indicate that activated, mature 
neutrophils and CD4 T cells may be responsible for causing significant reduction in gene 
expression observed in the Bb-infected mice. In particular, the presence of the CD4 T cells may 
29 
 
be playing the more significant role, as that cell type was not present at the earlier AAV 
administration time point (day 2 post-infection), which reduced gene expression by only ~3-fold.   
Additionally, it is worthwhile to note that one of the elevated cytokines on day 14 of the 
chronic infection, IL-17, is produced by CD4 T cells and has been implicated in the stimulation of 
airway mucin gene expression [41]. This could suggest the development of an enhanced mucus 
barrier by day 14 of the chronic infection. Such a phenomenon could explain the significant loss 
in gene transfer efficiency at this later time point for AAV administration. The enhanced mucus 
layer would prevent transduction by hindering normal transport of vector to the target cells.  
In several studies, AAV vector administrations targeting liver have proven to be safe and 
rarely elicit an immune response, even when challenged with an adenovirus expressing a similar 
transgene [42,43]. However, co-administration of TLR ligands, including CpG-containing ODNs, 
along with antigen-specific T cells or adenoviruses led to loss of liver transgene expression 
[42,43]. It is likely that in our models, the inflammatory microenvironment and cytokine release 
profile following bacterial infections may have resulted in the breaking of immune tolerance to 
AAV particles and/or their gene products. Hence, the bacterial presence in our infection models 
likely serves as a form of adjuvant, triggering sufficient immunity to the AAV vector and/or to 
the ffluc product to result in a diminished expression or visualization thereof.  
In each of our models, free bacteria were administered to the nares of healthy mice to 
facilitate a prolonged infection of the respiratory tract. The administration of free bacteria 
contrasts with the established practice of artificially embedding bacteria in agar beads before 
depositing them into the airway through a tracheal incision. The methods presented here are thus 
simpler and less invasive. Additionally, our methods do not limit the infection to the conducting 
airways, which is not the case with methods involving embedded beads. Due to their size, the 
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beads create a mechanical block to the bronchi, resulting not only in limited bacterial access to 
the respiratory airways but also in increased morbidity, unwanted lung damage, and potentially 
even collapse or closure of the lung [44].  
To the best of our knowledge, this the first study to examine the effects of an active, naturally 
occurring respiratory infection on AAV airway gene transfer. Our findings clearly show that the 
efficiency of AAV-mediated gene transfer in the airway is negatively impacted by the presence of 
an on-going or recently resolved bacterial infection. These results underscore the importance of 
considering such circumstances when developing potential genetic treatments for relevant 
diseases, like CF and potentially other airway diseases such as asthma. The methods validated 
here provide simple and minimally invasive techniques that will allow this type of infected 
environment to be more easily accounted for. 
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3.0 Synthesis and structure-activity relationships of novel cationic lipids 
with anti-inflammatory and antimicrobial activities 
3.1 Abstract 
 
Certain membrane-active cationic steroids are known to also possess both anti-
inflammatory and antimicrobial properties. This combined functionality is particularly relevant 
for potential therapies of infections associated with elevated tissue damage, e.g. cystic fibrosis 
airway disease, a condition characterized by chronic bacterial infections and ongoing 
inflammation. In this study, six novel cationic glucocorticoids were synthesized using 
beclomethasone, budesonide, and flumethasone. Products were either monosubstituted or 
disubstituted, containing one or two steroidal groups, respectively. In vitro evaluation of 
biological activities demonstrated dual anti-inflammatory and antimicrobial properties with 
limited cytotoxicity for all synthesized compounds. Budesonide-derived compounds showed the 
highest degree of both glucocorticoid and antimicrobial properties within their respective mono- 
and disubstituted categories. Structure-activity analyses revealed that activity was generally 
related to the potency of the parent glucocorticoid. Taken together, these data indicate that these 
types of dual acting cationic lipids can be synthesized with the appropriate starting steroid to 
tailor activities as desired. 
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3.2 Introduction 
 
Pathophysiological symptoms of CF airway disease are cyclic in intensity, with the more 
intense periods termed “exacerbations.” Such exacerbations are associated with high bacterial 
(usually,  P. aeruginosa) concentrations in the airway sputum, and aggressive antibiotic treatment 
is typically required to improve lung function [45,46].  However, while early P. aeruginosa 
infections are susceptible to common anti-pseudomonal antibiotics (e.g. β-lactam antibiotics, 
aminoglycosides, and fluoroquinolones), later infections are more difficult to treat as antibiotic 
resistance emerges with the patient’s age [8]. Resistance develops under the pressure of continued 
heavy use of antibiotics and is linked to increased occurrence of hypermutable P. aeruginosa 
isolates [47]. The emergence of these isolates is associated with the ongoing oxidative stress 
caused by the chronic polymorphonuclear leukocyte inflammation typical of many CF patients 
[48]. Thus, a novel antibiotic with a dual anti-inflammatory function may prove useful for 
treating and preventing additional exacerbations of CF airway disease. 
 Previous cationic sterol-based cationic lipids synthesized by our laboratory, 
dexamethasone spermine (DS)[23] and disubstituted dexamethasone spermine (D2S)[49], 
exhibited dual antimicrobial and anti-inflammatory functions. This study presents the synthesis 
and characterization of six new cationic steroids of similar structure to further understanding of 
this family of compounds. Instead of dexamethasone (dex), the six novel lipids presented (Figure 
3.1) here contain other glucocorticoids (GCs) as the steroidal side groups: beclomethasone in BeS 
and Be2S, budesonide in BuS and Bu2S, and flumethasone in FS and F2S. These cationic lipids 
were the result of linking a polyamine, i.e. spermine, to the 21-OH position of each steroid. 
Products from this linkage reaction were either monosubstituted or disubstituted, with linkages 
occurring at one or both terminal amino groups of spermine, respectively. Compounds were 
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evaluated for glucocorticoid, antimicrobial, and DNA lipofection activities, as well as for any 
potential cytotoxic effects on mammalian cells.  
 
Figure 3.1: Structures, molecular weights, and CLogP values of FS, F2S, BuS, Bu2S, BeS, and Be2S.   
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3.3 Materials and Methods 
 
3.3.1 Synthesis of Beclomethasone-21-mesylate and Flumethasone-21-mesylate 
A 125-mL Erlenmeyer flask was filled with 1 g of the desired GC, 3.2 mL of anhydrous 
pyridine, and 240 µL of methanesulfonyl chloride. The flask was kept at 0°C with an ice bath and 
stirred continuously with a magnetic stir bar. After 1 hour, an additional 160 µL of 
methanesulfonyl chloride was added and an additional hour was allowed to elapse. The solution 
was then poured into 20 mL of ice-cold 1 M HCl, causing precipitation. The solid was filtered out 
and then re-dissolved into 50 mL of ethanol. Precipitation was facilitated again by pouring the 
solution into 50 mL of 1 M HCl. The precipitate was filtered out one last time, recrystallized in 
ethanol, filtered, and dried overnight before further processing.  
3.3.2 Synthesis of Cationic Glucocorticoids 
BeS, Be2S, BuS, Bu2S, FS, and F2S were prepared using a reaction scheme previously 
described for the synthesis of DS and D2S [23]. Briefly, the 21-mesylate form of each steroid was 
reacted separately into its mono- and di-substituted cationic products via a one-pot reaction 
involving molar excesses of both spermine and Traut’s reagent (2-iminothiolane HCl) in ethanol 
at 40°C. Beclomethasone-21-mesylate and flumethasone-21-mesylate were synthesized as 
described earlier, and budesonide-21-mesylate was obtained from Steraloids (Newport, RI). 
Spermine and Traut’s reagent were obtained from Sigma-Aldrich. The reaction was allowed to 
proceed for ~1 hour before being quenched with trifluoroacetic acid (Sigma-Aldrich). Ethanol 
was removed through evaporation under vacuum, and the reaction products were dissolved in 
water before the purification process. 
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3.3.3 Semi-preparative Purification of Reaction Products 
A Shimadzu (Columbia, MD) LC-MS system was used to purify desired products from 
the crude reaction mixture. This system included an LC-20AB pump for solvent delivery 
connected to a SIL-20A autosampler, which was coupled to a SPD-20A for dual wavelength UV-
Vis detection and a LCMS 2010EV mass spectrometer. A Hamilton (Reno, NV) PRP-1 column 
(250 x 10 mm i.d., 10- µm particle size) was used with this LC-MS to facilitate separation. The 
mobile phase flow rate was 4 ml/min with a starting ratio 95% mobile phase A (water) and 5% 
mobile phase B (acetonitrile). For the beclomethasone- and flumethasone-derived products, the 
elution profile consisted of an isocratic step to 13% phase B for 35 minutes and then another 
isocratic step to 20% phase B for an additional 35 minutes. For separation of the budesonide 
products, the first step of the elution profile is the same at 13% phase B for 35 minutes, but the 
second step uses 25%, in lieu of 20%, phase B for the same amount of time. Solvent from 
collected fractions was removed via lyophilization, and final products were resuspended in 
nuclease-free water at concentrations between 10 and 20 mg/ml.  
3.3.4 Analytical Characterization 
Analytical characterization was performed with the same Shimadzu LC-MS system 
coupled to a Hamilton PRP-1 column (150 x 4.6 mm i.d., 5- µm particle size). The mobile phase 
flow rate was 1 ml/min with a starting composition of 95% mobile phase A (water) and 5% 
mobile phase B (acetonitrile). The elution profile for the beclomethasone- and flumethasone-
derived products consisted of an isocratic step to 13% phase B for 25 minutes and then a second 
step to 20% phase B for an additional 25 minutes. For the budesonide-derived products, the 
second step utilized 25% phase B. Results from the mass spectrometer was used to assess purity 
of eluent. 1H and 13C NMR analyses were performed using an AVANCE III 500 MHz 
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instrument (Bruker, Newark, DE) using a dual 5-mm cryoprobe. The calculated log values of the 
octanol/water partition coefficient, i.e. ClogP values, were predicted with ChemBioDraw Ultra 
software (Cambridgesoft) using fragmentation methods. 
3.3.5 Cell Culture 
Bovine aortic endothelial cells (BAECs) and A549 cells were cultured at 37°C and 5% 
CO2 in DMEM supplemented with 10% FBS, 2% penicillin/streptomycin, and 1% L-glutamine 
(all materials from Gibco, Life Technologies). All experiments were conducted with cells seeded 
24 hours before any treatment at 50-75% confluence in 96-well plates.  
3.3.6 Nuclear Localization of the Glucocorticoid Receptor 
Ability to trigger nuclear localization of the GC receptor (GR) was visualized by 
transfecting BAECs with pGFP-GR, a plasmid encoding for a green fluorescent protein (GFP)-
GR chimeric protein. Cells were seeded as described earlier and allowed to spread overnight. 
Transfections were then conducted with Lipofectamine 2000 (Life Technologies), according to 
the manufacturer’s instructions. DNA-Lipofectamine complexes were incubated with cells for 
two hours before the growth media was replaced with DMEM supplemented with 0.5% charcoal-
treated FBS to prevent non-specific cellular responses to hormones in the serum. After an 
additional overnight incubation, cells were treated with cationic GCs at the specified 
concentrations (0.01 -1 μM) for approximately 1 hour before being imaged using light and 
fluorescence microscopy (IX81; Olympus America). Total cellular fluorescence and nuclear 
localized fluorescence were calculated with ImageJ (NIH) for at least 10 cells per condition. 
These values were used to determine the average percentage of nuclear localized cellular 
fluorescence per condition.  
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3.3.7 Induction of the Glucocorticoid Response Element 
Ability to induce the GC transcriptional response element (GRE) was analyzed by 
transfecting BAECs with pGRE-SEAP, a plasmid containing the gene for a secreted embryonic 
alkaline phosphatase (SEAP) under transcriptional control of the GRE. BAECs were transfected 
using the procedure described earlier for pGFP-GR transfection. After replacement of the media 
with DMEM containing 0.5% charcoal-treated FBS, cells were incubated overnight. Growth 
media was then refreshed with fresh media containing the specified concentrations of the 
synthesized cationic lipids (1 or 5 μM). Cells were treated with the lipids for 24 hours before the 
media was harvested and stored at -20°C until further processing for SEAP quantification, which 
was conducted using the Great EscAPe™ SEAP Chemiluminescence Reporter Kit 2.0 (Clontech) 
according to the manufacturer’s instructions. Chemiluminescence was measured with an 
EnVision Multilabel Plate Reader (PerkinElmer Life and Analytical Sciences, Waltham, MA). 
3.3.8 Antibacterial Activity 
Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations 
(MBCs) were determined using bacteria in their logarithmic phase of growth. Compounds were 
tested against the following bacteria: MRSA strain Xen30 (Caliper Life Sciences), Escherichia 
coli, and various strains of Pseudomonas aeruginosa, i.e. PA14, Xen5 (Caliper Life Sciences), 
and ten clinical strains isolated from CF sputum. Clinical strains were collected by spontaneous 
expectoration from patients attending the Adult Cystic Fibrosis Center, University of 
Pennsylvania Health System (IRB 803255). When necessary, samples were diluted with PBS and 
vortexed in the presence of glass beads to produce homogenous solution. Known antimicrobial 
agents tobramycin (TOB), cathelicidin LL-37 (Peptide 2.0), DS, and D2S, were also tested to 
provide reference MIC and MBC values. MIC/MBC values were determined in Luria-Burtani 
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(LB) media using the microdilution methods. Bacteria were incubated at 37°C for 18-24 hours 
before being treatment. MIC values were determined against bacterial concentrations of ~5 x 105 
CFU/ml, and MBC values were performed by plating each sample on appropriate solid agar 
mediums.  
3.3.9 Preparation of Liposomes and Lipoplexes 
Liposomes were formed by combining lipids with a neutral lipid, 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (Avanti Polar Lipids) in a 1:1 molar ratio, as previously 
described [49]. Briefly, the neutral lipid in chloroform was added to a glass tube, and the solvent 
was removed under vacuum to generate a lipid film. The film was rehydrated with sterile water 
containing appropriate amounts of the desired cationic lipids. Mixtures were then probe-sonicated 
for 30 seconds and briefly vortexed before use. Lipoplexes were formed by diluting the liposomes 
into an equal volume of Opti-MEM® I Reduced Serum Media (Life Technologies) containing 
plasmid DNA at the appropriate concentration. Lipoplexes were formed 15 minutes before use in 
all experiments.  
3.3.10 Transfection and measurement of EGFP  
Lipoplexes were used to transfect BAECs and A549 cells, separately, to determine 
transfection abilities of synthesized lipids. Plasmid DNA, pGFP-N3 (Clontech), was transfected 
to generate GFP as a fluorescent transgene reporter protein. Lipofectamine 2000 in a 2:1 (w/w) 
ratio with DNA was used as the positive control for both cell lines, and plasmid DNA without any 
cationic lipid was used as the negative control. Cells were transfected in quadruplicate in 96-well 
plates, 24 hours post-seeding. Media was removed, and cells were washed once with sterile PBS 
before being treated with lipoplexes. After three hours of treatment, media was aspirated and 
replaced with fresh DMEM without any antibiotics. After 24 hours, cells were harvested and 
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processed with flow cytometry to determine the percentage of cells positive for GFP. A BD 
Accuri™ C6 flow cytometer was used for this analysis 
3.3.11 Effects on Cell Viability 
A549 and BAECs cells were seeded on 96-well plates and allowed to spread overnight, 
as described earlier. Growth media was then replaced with media containing specified 
concentrations of lipids (0.01 – 50 μM), and cells were incubated for 24 hours. A CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega) was then used to evaluate cell viability after 
treatment, according to the manufacturer’s instructions. Luminescence was measured with an 
EnVision Multilabel Plate Reader Reader (PerkinElmer Life and Analytical Sciences, Waltham, 
MA). 
3.3.12 Red Blood Cell Hemolysis  
Hemolytic activities of synthesized cationic lipids were tested against human red blood 
cells (RBCs) collected from fresh blood, obtained in accordance with University of 
Pennsylvania’s IRB. Whole blood was anti-coagulated in citrate concentrated solution (9 parts 
whole blood to 1 part citrate solution, SigmaAldrich), and then centrifuged for 5 minutes at 
500xg. Plasma was removed, and the remaining hematocrit layer was resuspended in 150 mM 
NaCl to wash the RBCs. Sample was centrifuged again at 500xg for 5 minutes and then washed 
an additional two times, first with 150 mM NaCl and then with fresh Tyrode’s solution without 
bovine albumin serum. After a final centrifugation cycle, a ~2% hematocrit suspension was 
achieved by diluting 1mL of RBCs into 49mL of fresh Tyrode’s solution. Compounds were 
added to 100 µL of this suspension to achieve the specified concentrations, and all samples were 
incubated for 1 hour at 37°C before centrifugation at 500xg for 5 minutes to pellet any intact 
RBCs. Supernatants were transferred into a clean 96-well plate, and relative hemoglobin (Hb) 
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concentration was quantified by measuring absorbance at 405 nm. To achieve 100% hemolysis, 
1% Triton X-100 was as a positive control to disrupt RBC membranes.  
3.4 Results 
 
A one-pot reaction with the appropriate GC mesylate, Traut’s reagent (TR), and spermine 
yielded the monosubstituted steroid (FS, BuS, or BeS) as the major product and the disubstituted 
steroid (F2S, Bu2S, or Be2S) as the minor product. The primary amines on either end of spermine 
reacted with TR to cause a selective ring-opening, resulting in an exposed sulfhydryl (-SH) end 
group. This end group then interacted with the α-keto mesylate of the modified GCs to form an α-
keto thioether linkage between the steroid and polycation tail (i.e. the spermine-TR conjugate), 
yielding the monosubstituted cationic steroid. To form the disubstituted product, the primary 
amine of the monosubstituted lipid reacted with another TR molecule to eventually result in 
another thioether linkage with a separate GC molecule.  
Desired compounds were purified from excess starting reactants and unwanted reaction 
intermediates with semi-preparative HPLC, and then their molecular weights and chemical 
structures were verified with mass spectroscopy (MS) and 1H and 13C NMR.  MS results are 
shown in Appendix A, Figures A1-A3. 
1
H and 
13
C NMR spectra and chemical shifts are also 
shown in Appendix B and Appendix C, Figures B1-B6 and C1-C6, respectively. Overall yield for 
the entire process (synthesis to purification) was ~60-70%, i.e. ~60-70% conversion of the parent 
steroid mesylate to the monosubstituted cationic product and a subsequent ~6-10% conversion of 
the monosubstituted product to the disubstituted product in a one-pot reaction. 
Hydrophobicity of compounds was also assessed through ClogP values, which are shown 
in Figure 3.1. Disubstituted products exhibited higher CLogP values than their monosubstituted 
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analogues. Budesonide-derived compounds showed the highest values, while flumethasone 
compounds showed the lowest.  
Ability to trigger some degree of nuclear localization of the GR was observed for all 
cationic lipids, though some exhibited more potency than others (Figure 3.2). Only budesonide-
derived compounds showed activity equivalent to that seen with the positive control dex. 
Flumethasone and beclomethasone compounds showed less potency than equivalent 
concentrations of dex at all values tested (p<0.01). GC character was further evaluated by 
measuring ability to induce expression of the GRE. Again, budesonide-derived products are the 
only compounds to achieve expression equivalent to that seen with dex (Figure 3.3). Interestingly, 
beclomethasone products showed a comparatively limited ability to trigger GRE induction; no 
cellular response was observed at 1 µM BeS or Be2S (data not shown). At 5 µM, Be2S trigged 
only a modest response, while BeS triggered no effect at all. Flumethasone-derived products were 
able to achieve equivalently limited responses at 1 µM for both FS and F2S.  
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Figure 3.2: Steroid-induced nuclear localization of GFP-GR in BAECs 
(A) GFP-GR translocation from cytosol to nucleoplasm. BAECs were transfected with pGFP-GR using Lipofectamine 
2000 and then treated with compounds to stimulate GFP-GR nuclear localization. (B) Quantitative evaluation of 
cellular fluorescence localized within the nucleoplasm after treatment. Cells were treated with dexamethasone (positive 
control), FS, F2S, BuS, Bu2S, BeS, and Be2S at various concentrations. After 4 hours of treatment, cells were imaged 
using fluorescence microscopy, and percentage of cellular fluorescence localized with in the nucleus was assessed 
using ImageJ. At least 10 cells per condition were evaluated. Results are presented as means, and error bars represent 
the standard deviation. All experimental compounds showed some degree of GC activity greater than the untreated 
control at all concentrations tested (** p<0.01, Student’s t-test). Only BuS (0.1-1 μM) and Bu2S (0.01-1 μM), however, 
showed activity equivalent to that seen at equivalent concentrations of the positive control dexamethasone. † † 
indicates statistical significance (p<0.01, Student’s t-test) when compared to dexamethasone. 
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Figure 3.3: Steroid-induced activation of GRE promoter in BAECs 
Cells were transfected with pGRE-SEAP using Lipofectamine 2000 and then treated with (A) 1 μM FS and F2S, (B) 1 
μM BuS and Bu2S, and (C) 5 μM BeS and Be2S to induce activation of the GRE-SEAP gene construct. After 24 hours 
of treatment, media was harvested and evaluated for SEAP levels. Results were normalized relative to the positive 
control, dexamethasone (dex), and are presented as means. Error bars represent the standard deviation. Only BuS and 
Bu2S showed GRE activation comparable to that seen with dex. Flumethasone and beclomethasone products, on the 
other hand, showed significantly less GRE activation (** p<0.01, Student’s t-test) than that seen with equivalent 
concentrations of dex.  
 
Bacteria killing abilities were tested against various strains of bacteria, including several 
clinical isolates of P. aeruginosa, and the determined MICs and MBCs, as well as MBC:MIC 
ratios, are presented in Tables 3.1A-B. For clarity, MBCs are also presented in a cluster heat map 
in Figure 3.4. While generally more effective against the gram-positive bacterium tested (MRSA 
Xen30), many of the monosubstituted products were unable to achieve inhibitory effects at 
concentrations less than 128 μg/ml with the other bacteria tested. BuS was the exception in this 
general trend, showing activity nearly equivalent to that seen with the more potent disubstituted 
products. Notably, BuS and all other disubstituted products displayed bactericidal activity greater 
than that observed with the positive controls, tobramycin and cathelicidin LL-37. Bu2S showed 
the greatest potency of all compounds tested.  
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Table 3.1: Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of selected 
steroids against various pathogens. 
(A) Specified pathogens were treated with FS, F2S, BuS, Bu2S, BeS, and Be2S as well as known antibiotic compounds, 
i.e. tobramycin (TOB), cathelicidin LL-37, DS, and D2S, to provide reference MIC and MBC values. Concentrations 
are in μg/ml. (B) Calculated MBC:MIC ratios. Single daggers (†) indicate ratios that could not be determined because 
the MBC and MIC values were both >256 μg/ml (i.e. determined without an exact value). Clinical isolates of P. 
aeruginosa (PA) in both tables are indicated by a single asterisk (*) 
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Figure 3.4: Cluster heat map of minimal bactericidal concentrations (MBCs, μg/ml) of cationic steroids against 
various pathogens. 
Specified pathogens were treated with FS, F2S, BuS, Bu2S, BeS, and Be2S as well as known antibiotic compounds, i.e. 
tobramycin (TOB), cathelicidin LL-37, DS, and D2S, to provide reference MBC values. Results are presented in a 
cluster heat map to visually associate compounds with similar activities. Patterned boxes indicate compound/pathogen 
combinations that were not determined (ND). Clinical isolates of P. aeruginosa (PA) are indicated by a single asterisk 
(*). 
 
Transfection activities of cationic lipids were assessed using mixtures of varying 
monosubstituted to disubstituted lipid ratios on BAECs or A549 cells. Results are shown in 
Figure 3.5. With either cell type, transfection mixtures containing only monosubstituted lipids 
showed zero to very little transfection activity. Mixtures containing only disubstituted products 
achieved transfection activity generally comparable to that seen with the positive control, 
Lipofectamine 2000. Interestingly, 60/40 and 40/60 mol% FS/F2S mixtures showed activity 
equivalent to that seen with 100% F2S with either cell type. For budesonide and beclomethasone 
compounds, trends in activity appeared to be cell specific. 40/60 mol% mono/disubstituted 
mixtures appeared more effective with BAECs, while 60/40 mol% mixtures were more effective 
with A549 cells.  
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Figure 3.5: Transfection of BAECs and A549 cells with FS, F2S, BuS, Bu2S, BeS, and Be2S using GFP transgene 
(A) BAECs and (B) A549 were transfected with cationic lipids at a charge ratio of 6:1 or Lipofectamine 2000 (i.e. 
Lipo2000, positive control) at a ratio of 2:1(w/w) ratio with DNA. Cells were harvested 24 hours later and sorted for 
GFP-positivity using flow cytometry. Results are represented as means, and error bars show the standard deviation 
from four replicates of 500-1000 events per condition. 
 
Compounds showed limited toxicity on BAECs and A549 cells at concentrations less 
than 50 μM (~30 μg/ml for monosubstituted compounds, ~60 μg/ml for disubstituted 
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compounds), as shown in Figure 3.6. At these lower concentrations, loss in cell viability was 
never greater than ~10% for BAECs and ~20% for A549 cells. Furthermore, toxic effects on 
viability never exceeded that which was seen with dex at equivalent concentrations. At 50 μM, 
however, much more dramatic effects were observed. Treatment with any disubstituted 
compound resulted in a dramatic loss in cell viability (85-100%) with either cell type. This degree 
of toxicity was not observed at 50 μM dex, although this concentration proved to be more toxic 
than lesser concentrations of the compound. Interestingly, monosubstituted products also did not 
exhibit this amount of cytotoxicity at 50 μM concentration. BuS treatment showed loss in 
viability comparable to that seen with dex at this concentration, while FeS and BeS barely caused 
a ~5-10% loss in viability. 
 
Figure 3.6 Cell viability post-treatment with FS, F2S, BuS, Bu2S, BeS, and Be2S.  
(A) BAECs and (B) A549 cells were treated with cationic lipids at the specified concentrations for 24 hours before cell 
viability was assessed. Results represent means, and error bars indicated standard deviation from four replicates at each 
condition. At concentrations below 50 μM, compounds showed limited toxicity, i.e. no more than 10% or 25% loss in 
viability with BAECs or A549 cells, respectively. Disubstituted products showed significant toxicity at 50 μM only, 
resulting in complete or near complete loss in viability with both cell types. In all other cases, toxicity was never 
greater than that observed with the dexamethasone control. ** indicates statistical significance (p < 0.01, Student’s t-
test) when compared to untreated control.  
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Toxicity toward eukaryotic cell membranes was assessed by measurement of Hb release 
from human RBCs, and results are shown in Figure 3.7. Significant Hb release was observed only 
with the higher concentrations (≥50 μM) of the disubstituted compounds. Bu2S caused the most 
Hb release at these concentrations, i.e. ~17% Hb release at 50 μM and ~36% release at 100 μM, 
while Be2S resulted in the least, i.e. 0% release at 50 μM and ~8% release a 100 μM. All 
monosubstituted products failed to cause >1% Hb release at all concentrations tested.  
 
Figure 3.7: Red blood cell lysis in response to treatment with FS, F2S, BuS, Bu2S, BeS, and Be2S 
Freshly isolated human RBCs were treated with specified amounts of cationic lipids, and hemoglobin (Hb) release was 
measured after one hour of treatment at 37°C. Results are represented as means, and error bars show the standard 
deviation from four replicates at each condition. Monosubstituted products show very little to no RBC hemolysis at all 
concentrations tested. Disubstituted products show hemolysis at concentrations greater than 50 μM. 
 
3.5 Discussion 
 
This report presents the synthesis and in vitro characterization of six novel cationic GCs 
with dual antimicrobial and anti-inflammatory character. These compounds are based on 
previously synthesized sterol-derived cationic steroids, DS and D2S, which also displayed 
antimicrobial and anti-inflammatory properties. Compounds presented here exhibited a range of 
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anti-inflammatory and antimicrobial activities without showing dramatic toxicities at the 
concentrations necessary to achieve desired activities.  
Disubstituted products generally demonstrated more potency than their monosubstituted 
analogue in many of the categories tested. This is an expected observation since the disubstituted 
products, as demonstrated by their CLogP values, are more lipophilic than their monosubstituted 
analogues. With higher hydrophobic character, these compounds are able to penetrate the 
hydrophobic core of a cell membrane more easily and trigger the appropriate response once inside 
the cell. This enhanced membrane activity is also reflected in their ability to trigger Hb release 
from RBCs at concentrations that triggered no such response with the monosubstituted products. 
Additionally, the greater anti-inflammatory activity of the disubstituted compounds can also be 
attributed to the presence of two steroidal side groups, rather than one. With an additional ligand 
to bind appropriate receptors, these compounds are more likely to bind and activate the cytosolic 
GR once they have bypassed the cell membrane.  
Interestingly, at concentrations above 0.01 μM, one monosubstituted compound, BuS, 
was able to achieve levels of GC activity equivalent to that observed with dex and its 
disubstituted counterpart (Bu2S) without demonstrating significant membrane disruption activity. 
At the concentrations tested (0-100 μM), treatment of RBCs with BuS did not cause any Hb 
release, indicating that the plasma membrane had not been compromised. Together, these 
phenomena suggest that BuS is membrane permeable without being membrane disruptive, as it 
must bypass the cell membrane in order to bind the cytosolic GR for GC activity. Likely, the 
smaller size of BuS, relative to that of the disubstituted compounds, allows it to pass through the 
membrane without disrupting the structural integrity.  
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GC activity is also known to correlate with the size and polarity of the substituent at the 
16 position [50]. Hydrophobic residues at this position, like the cyclic butryaldehyde-containing 
acetal group of budesonide, result in higher GC potency. In fact, unmodified budesonide 
demonstrates GC activity that is ~10 times more potent than that of dex [50] and a GR affinity for 
that is ~8 times the GR affinity of dex [51]. Unmodified flumethasone and beclomethasone have 
GC activities that are only 2-3 times higher than GC activity of dex [50]. Consequently, the 
comparatively high degree of GC activity of BuS and Bu2S is not particularly surprising. 
However, the lack of GC activity from flumethasone- and beclomethasone-derived compounds is. 
This effect suggests that addition of the cationic tails to these steroids either results in decreased 
membrane permeability or decreased GR affinity. The fact that BuS, a monosubstituted analogue, 
is able to effectively trigger GC activity suggests that this effect is not due to a loss in membrane 
permeability. FS and BeS are likely just as able to penetrate the cell membrane but are ultimately 
unable to bind the GR without sufficient affinity for activation. 
The trends observed in bacteria killing ability are generally analogous to those seen with 
GC activity. The disubstituted compounds are more effective than their monosubstituted 
counterparts, and the explanations are likely the same, despite the differences in lipid membrane 
constituents in prokaryotic and eukaryotic cells. Disubstituted compounds are larger and more 
hydrophobic, enabling them to more easily associate with a lipid bilayer membrane and cause 
disruptions in the structural integrity when they do so. Notably, however, BuS once again shows 
unexpectedly high activity. Despite being less effective than its disubstituted counterpart, it was 
much more effective than any of the other monosubstituted compounds tested. In fact, the 
antimicrobial activity of BuS was more comparable to that of the disubstituted compounds than 
that of the monosubstituted ones. BuS is thus a particularly promising candidate for a future 
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therapeutic because it exhibits high potencies in GC and antimicrobial activity but little in 
cytotoxic and hemolytic activity.  
Results from the bacteria killing assay also demonstrated two other key findings. First, 
BuS and all disubstituted compounds tested were generally more effective at killing the tested 
pathogens than antimicrobial compounds cathelicidin LL-37 and tobramycin were, and the latter 
is frequently used to treat bacterial infections during CF airway exacerbations. Second, all 
compounds of this study, both mono- and disubstituted, showed particularly high efficacies 
against the Gram-positive bacterium MRSA Xen30. Gram-positive bacteria are generally more 
susceptible to cationic lipids [52], but they may show especial susceptibility with cationic 
antibiotics because of their peptidoglycan outer layer. Anionic polymers, i.e. teichoic acids, are 
exposed on the surface of Gram-positive bacteria and thread through their peptidoglycan outer 
layer. They impart to it a negative charge that facilitates easy association with cationic antibiotics. 
Gram-negative bacteria, on the other hand, have an outer membrane layer that contains LPS 
molecules, which reduce the fluidity, and thus the permeability, of the membrane. LPS typically 
allows resistance against hydrophobic antibiotics for this reason, but the antibiotics presented 
here are also cationic in nature. This characteristic likely enables them to weaken the LPS 
structure by displacing the divalent cations (Ca
2+
 and Mg
2+
) that normally stabilize it, thereby 
allowing permeabilization of the outer membrane that render the bacteria unviable.  
Transfection activity of the cationic steroids was also assessed, and while no compound 
was more efficacious than the commercially available Lipofectamine 2000, many of the 
formulations tested showed comparable activity. Those formulations could therefore be used to 
facilitate equivalent gene transfer while also effecting anti-inflammatory and antimicrobial 
changes as well. The value of these compounds is not in enhancing any single particular effect 
but in achieving simultaneous actions with a single formulation.  
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The compounds presented here offer a unique advantage in treating infections associated 
with elevated tissue inflammation. As novel antibiotics with dual anti-inflammatory and 
bactericidal activities, they are able to treat the infection itself as well as the inflammatory 
environment that promotes the development of hypermutable bacteria strains and antibiotic 
resistance. The abilities of these compounds to facilitate gene transfer provide additional value 
with treatments that target the relevant diseases at their genetic source. More notably, however, 
the results presented here additionally demonstrate that these compounds can be synthesized with 
different parent glucocorticoids to produce cationic steroids that retain their dual functionalities 
but achieve potencies that correlate with that of the starting steroid. Synthesis of these lipids can 
thus be modified accordingly to tailor potential treatments for a variety of applications and 
potencies.  
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4.0 Coordinated cationic glucocorticoid treatment with adeno-
associated virus gene transfer during acute airway infection 
4.1 Abstract 
 Airway bacterial infections, whether currently on-going or recently resolved, are known 
to reduce efficacy of airway gene transfer by certain viral vectors. This effect is particularly 
detrimental for the development of genetic therapies for cystic fibrosis airway disease, which is 
characterized by chronic infections with opportunistic bacteria and associated inflammation.  In 
this study, negative effects of infection were partially reversed by coordinating gene transfer with 
pre-treatments involving anti-inflammatory and antimicrobial cationic glucocorticoids.  These 
cationic glucocorticoids, budesonide spermine and disubstituted budesonide spermine, were 
formulated into liposomes with a neutral lipid and administered to Pseudomonas aeruginosa 
PAO1-infected mice 24 hours before treatment with an adeno-associated virus vector. All mice 
treated with cationic liposomes showed higher expression levels of the reporter gene, and one 
mouse even showed expression higher than that seen with healthy, uninfected mice. These results 
confirm that cationic glucocorticoid treatment can be coordinated with gene therapies for CF 
airway diseases to regain gene transfer efficiency that was lost due the presence of infection.   
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4.2 Introduction 
 As discussed earlier, infections negatively impact gene transfer in the airway, regardless 
of whether they are currently on-going or recently resolved at the time of gene administration, 
and the mechanism behind this observed effect was linked to the immune response occurring at 
the time of gene delivery [53]. These observed phenomenon have strong implications for 
potential gene therapies of CF airway disease, a condition characterized by on-going infection 
and concomitant inflammation. Without first addressing this hostile environment for gene 
transfer, successful gene transfer for treating the underlying genetic disease is likely 
unachievable. The multifunctional cationic glucocorticoids discussed in chapter 2 have particular 
potential for such applications, as they possess anti-inflammatory and antimicrobial activities in 
addition to their abilities to facilitate gene transfer.  
 In this study, treatment with two cationic glucocorticoids, BuS and Bu2S, was 
coordinated with AAV-mediated gene transfer in SP-A KO mice transiently infected with P. 
aeruginosa PAO1. BuS and Bu2S were the most likely candidates to perform well in vivo due to 
their encouraging potencies observed in vitro. These cationic glucocorticoids were formulated 
into liposomes with a neutral lipid, DOPE, and then intranasally delivered to mice 24 hours 
before AAV administration. Loss in gene expression in pre-treated groups was only a fraction of 
that observed in infected, untreated mice. These results confirm that cationic glucocorticoids can 
be coordinated with gene therapies of CF airway disease to produce beneficial results.    
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4.3 Materials and Methods 
4.3.1 Mice 
C57BL/6 male mice were purchased from Charles River Laboratories (Wilmington, MA), 
while SP-D and SP-A knockout mice [40] were maintained in-house at the University of 
Pennsylvania. For all experiments, a group size of at least 3 mice was used for each experimental 
cohort. All animals were maintained at the Animal Facility of the Translation Research 
Laboratories at the University of Pennsylvania under protocols reviewed and approved by the 
University of Pennsylvania’s Institutional Animal Care and Use Committee. Prior to all intranasal 
administrations, mice were anesthetized by an intraperitoneal injection of ketamine/xylazine 
(70/7 mg/kg). 
4.3.2 Preparation of Cationic Liposomes 
Separately, BuS and Bu2S were synthesized and combined with neutral lipid DOPE 
(Avanti Polar Lipids) in a 1:1 molar ratio to form liposomes, as described earlier. Briefly, the 
neutral lipid in chloroform was added to a glass tube, and the solvent was removed under vacuum 
to generate a lipid film. The film was rehydrated with sterile water containing appropriate 
amounts of the desired cationic lipids. Mixtures were then probe-sonicated for 30 seconds and 
briefly vortexed. Liposomes were then diluted 10x into PBS to achieve the appropriate 
concentration. Lipids were formulated 30 minutes before use and kept on ice until administration 
to animals. 
4.3.3 AAV Preparation 
The AAV9 vectors flanked with AAV2 inverted terminal repeats (ITRs) contained a 
firefly luciferase (ffluc) reporter gene fused to a nucleus localization sequence at the N-terminus 
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under the transcriptional control of the cytomegalovirus (CMV)-enhanced chicken-β-actin 
promoter. Vectors were produced by the Penn Vector core as previously described [39].  
4.3.4 Preparation of PAO1 Inoculum 
P. aeruginosa PAO1 was cultured at 37°C in Miller’s Lysogeny Broth (LB) (Mediatech, 
Herndon, VA) or on cetrimide agar from Sigma Aldrich. Bacteria were grown overnight in LB at 
37°C with shaking at 250 rpm. Approximately 16-18 hours later, the bacteria were diluted into 
fresh broth to an optical density (OD) (λ=600nm) reading of 0.1 and were allowed to grow until 
mid-logarithmic phase (OD600=~0.4). At that point, the bacteria were harvested and washed once 
in phosphate-buffered saline (PBS) before being diluted into fresh PBS at the desired 
concentration (controlled by evaluation of optical density at 600 nm).  
4.3.5 Airway Infection with PAO1 and Treatment with Cationic Liposomes and AAV 
Before challenge, mice were anesthetized intraperitoneally as described earlier. Mice 
were then intranasally (i.n.) challenged with a 20-µL bolus (delivered as two 10 µL aliquots, one 
into each nostril) with P. aeruginosa PAO1 to achieve approximately 10
6 
CFU/mouse. At 24 
hours post-infection, mice received 20 μL of cationic liposomes at specified concentrations. After 
an additional 24 hours, mice were i.n. administered 5 × 10
10
 genome copies (GC) of AAV vector 
in 20 µL (10 µL into each nostril). 
To evaluate ffluc expression, mice (~20 grams) were anesthetized and suspended before 
20 µL of D-luciferin (15 mg/mL) was i.n. administered as two 10 µL aliquots, one into each 
nostril. After 5 minutes, mice were imaged for 60 seconds with the IVIS Xenogen imaging 
system. Quantification of signal was calculated with the Living Image 2.5.1 software.  
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4.3.6 Evaluation of Bacterial Load 
Samples of nasal lavage fluid (NLF) were taken from each randomly selected mouse 
(n=2-3 per group) at the time of AAV administration to evaluate bacterial load. Mice were 
decapitated and a cannula attached to a 1-mL syringe containing 300 µL of sterile PBS was 
placed into the tracheal remnant. PBS was then flushed through the nasal passages and collected 
through the nares into a 1.5-mL tube. This recovered fluid was used to flush the nasal cavity 
another two times, for a total of three flushes. All samples were kept on ice until further 
processing. To determine the CFU counts in each sample, 50-microliter aliquots of each sample 
were plated on solid selection agar for P. aeruginosa and incubated at 37°C for 16 hours. The 
number of colonies was then counted, and the total CFU count of each sample was back 
calculated from that number.  
4.4 Results 
 SP-A KO mice were infected with ~106 CFU PAO1 per mouse, treated with cationic 
liposomes (50µM BuS/DOPE or 25µM Bu2S/DOPE) 24 hours later, and then finally given 
AAV9.ffluc 48 hours after initial infection with PAO1. A randomly selected group of mice (n=2-
3) were tested for bacterial load at the time of AAV administration (Figure 4.1A). Interestingly, 
while the BuS/DOPE treated group showed a lower average bacterial load compared to the 
untreated group, the difference was not significant. Additionally, the Bu2S/DOPE treated group 
showed no difference compared to untreated mice.  
Significant differences, however, were observed in reporter gene expression, when 
measured with live whole-animal luminescent imaging one week later (n=3, Figure 4.1B).  
Although differences were not significant for the BuS/DOPE treated group, mice, on average and 
individually, showed higher levels of ffluc expression than that seen in infected, untreated mice. 
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Two of these mice showed ~1.5-fold higher expression than infected, untreated mice, and the last 
mouse showed ~6-fold higher expression. This high expression value was even two-fold higher 
than that seen in the healthy mice. Recovery in gene expression was much more uniform in the 
Bu2S/DOPE treated group, and average expression was significantly higher (~1.7-fold) than that 
observed in the infected, untreated group (p<0.01, Student’s t-test).  
 
Figure 4.1 Effects of cationic glucocorticoid pre-treatment on AAV9-mediated transduction during acute 
Pseudomonas aeruginosa PAO1 respiratory infection in SP-A KO mice  
(A) PAO1 colonization in SP-A KO mouse airway with or without cationic liposome pre-treatment. Approximately 106 
CFU of bacteria were i.n. delivered to mice, and ~24 hours later, mice were treated with 20 µL of BuS/DOPE or 
Bu2S/DOPE cationic liposomes at the specified concentrations. After an additional 24 hours, i.e. 48 hours after initial 
infection, bacterial load was measured through harvest of NLF from randomly selected mice. Samples from the 
BuS/DOPE-treated group showed the lowest average bacterial load, but differences were not determined to be 
significant. Results are shown as means, and error bars represent the standard deviations for n = 2-3mice in each group 
(n = 3 for the PBS-treated group and the BuS/DOPE-treated group; n = 2 for the PAO1-only-treated group and the 
Bu2S/DOPE-treated group). (B) AAV9-mediated transduction in PAO1-infected SP-A KO mice with or without 
cationic liposome pre-treatment. Two days after PAO1 infection (24 hours after cationic liposome treatment) mice were 
i.n. dosed with AAV9.ffluc. One week later, mice were imaged for gene expression.  Plots show quantification of 
luminescence for mouse nasal cavity of each mouse imaged (n=3 for all groups). The PAO1-only-treated group and 
Bu2S/DOPE-treated group showed significantly lower signal than the uninfected, PBS-treated mice did (**p<0.01, 
p<0.05, Student’s t-test). Importantly, however, expression in the Bu2S/DOPE group, while lower than that of the 
uninfected mice, was significantly higher than that seen in the untreated, infected group (i.e. PAO1-only-treated group, 
††p<0.01, Student’s t-test).  The BuS/DOPE group showed less uniform increases over the PAO1-treated group, and 
differences between that or the PBS-treated group were determined to be insignificant.  
4.5 Discussion  
 Coordination of gene therapies for CF airway disease with dual functioning anti-
inflammatory, antimicrobial cationic lipids could be an effective means for creating viable 
genetic therapies of this monogenic disease. These lipids could potentially treat not only the local 
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respiratory infection often seen with many CF patients, but they could also potentially address the 
concomitant hyperinflammation that so characteristically defines these patients as well. The 
preliminary results described here in this study validate the potential of using sterol-based 
cationic lipids to enhance potential gene therapies of CF airway disease.  
Pre-treatment with BuS/DOPE or Bu2S/DOPE liposomes at 24 hours before AAV 
administration during an active PAO1 infection resulted in partial restoration of reporter gene 
expression to normal levels seen in uninfected mice. While these differences were not significant 
in the BuS/DOPE group, none of the mice in this group showed lower expression than any of the 
mice in the untreated, infected group (n = 3 for both groups). Statistical significance could not be 
attained due to high variability in expression due to a single high expressing mouse. Notably, this 
high expresser displayed reporter gene expression that was two-times greater than that observed 
in the healthy group. Thus, while differences were not significant, trends indicate that BuS/DOPE 
treatment was beneficial for restoring or even enhancing gene expression to normal levels. Repeat 
studies with greater n-values are required to determine true variability of treatment and potential 
reasons why such dramatic variability exists.  
Interestingly, the Bu2S/DOPE-treated mice did show significantly higher gene expression 
than the infected, untreated group. Preliminary analysis of bacterial load, however, showed 
limited efficacy of the Bu2S/DOPE liposome to reduce bacterial load at the time of AAV 
administration at the concentration tested, i.e. 25 µM (n=2). This was half the concentration used 
for the BuS/DOPE formulations, which showed more obvious reduction in bacterial load at 50 
µM (n=3). Higher concentrations of Bu2S were not tested due to toxicity observed in vitro 50 µM. 
Regardless, the observed results suggest that gene expression can be restored to normal levels 
without reducing overall bacterial load. However, our current experimental protocol prevents us 
from assessing both bacterial load and gene expression in the same mouse, and with such 
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variability in effects, we cannot determine with certainty whether this conclusion is valid. Mice 
selected for analysis of gene expression may have had lower bacterial loads than those taken for 
bacterial load analysis, thereby skewing the true results. Additional experiments are required to 
further investigate these effects with larger n-number.  
 The results presented here are preliminary in nature, but they show potential in validating 
the use of cationic glucocorticoids to enhance gene therapies of CF airway disease. Additional 
studies with larger cohorts to determine true significance of events. Importantly, however, all of 
the infected mice treated with cationic liposomes showed higher expression than untreated, 
infected mice. Future studies should address the mechanism behind this observed effect by more 
complete analysis of effects on bacterial load as well as characterization of effects on immune 
response at the time of AAV administration.  
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5.0 Conclusions and Future Work 
5.1 Conclusions 
 A viable genetic therapy for cystic fibrosis airway disease does not yet exist, despite the 
more than 20 years that have elapsed since the discovery of the single gene that causes the 
disease. The lack of a convenient animal model to test potential therapies has hindered progress to 
a successful approach. The current work addresses this issue by establishing three different mouse 
models of airway infection, one chronic and two acute, to study the effects of infection on 
potential therapeutic methods. Individually, these models capture different aspects of clinical 
manifestations of CF: chronic infection, exaggerated inflammatory responses, and/or less 
effective clearance of bacteria from the airway. In each model, efficiency of AAV9-mediated 
transduction was decreased by ~2.5- to 3-fold when AAV was administered on day 2 of infection. 
Postponing administration of the vector to a later time point gave different results in the chronic 
and acute infection models. During the chronic infection, postponement resulted in an even 
greater loss in transduction efficiency (~8-fold), while during the acute infection, the result was 
the opposite, i.e. partial regain of efficiency was observed.  In both cases, loss in efficiency was 
linked to immune responses occurring at the time of AAV administration. Notably, the more 
dramatic loss in gene expression at day 14 was associated CD4 T cells and IL-17 secretion, which 
is associated with stimulation of airway mucus production.  
 This work is the first to show the negative effects of active infection on AAV-mediated 
gene transfer, and the implications are serious. Optimal therapeutic efficacy of gene therapies for 
CF airway disease cannot be achieved unless these effects are addressed as part of the treatment. 
Previous work in this lab demonstrated that sterol-based cationic lipids could be useful as 
adjunctive treatment to potential CF gene therapies. These lipids not only facilitated gene transfer 
but also demonstrated both anti-inflammatory and antimicrobial characteristics as well. In this 
62 
 
study, six additional cationic glucocorticoids were developed and characterized to further 
understanding of this family of compounds. Results revealed that lipids exhibited potencies that 
correlated to that of the parent glucocorticoid. Additionally, the two lipids that showed the highest 
potencies in vitro, BuS and Bu2S, were particularly ideal for applications in treating airway 
disease due to the low ratio of systemic to local activity of the parent glucocorticoid, budesonide. 
Logically, this work concludes with the evaluation of these cationic glucocorticoids on 
reversing the negative effects of infection on AAV-mediated gene transfer. Preliminary results 
were encouraging; all mice that received BuS or Bu2S pre-treatment 24 hours before AAV 
administration displayed higher gene expression than that seen with infected mice untreated with 
lipid. Interestingly, one mouse treated with BuS showed enhanced gene expression over that seen 
with healthy mice. Generally, however, restoration of gene expression was only partial. Lipid 
treatment was able to reduce the loss in expression by ~25-47% in all other treated mice.  
5.2 Future Work 
BuS and Bu2S, thus, show strong potential for enhancing AAV-mediated gene transfer in 
an infected environment. Additional studies, however, are required to more accurately 
characterize these effects and the mechanisms behind them. Experiments need to be repeated with 
larger n-value to determine true significance of events. Studies should also include 
characterization of the immune response at the time of AAV administration to evaluate any 
effects on inflammation. Methods to further enhance the therapeutic value of these coordinated 
gene therapies can also be investigated. Such methods could include varying the dosages and 
dosing schedule of the administered lipids. Dosages should differ by total concentration as well as 
by composition of mono- to disubstituted compounds. Eventually, lipids can also be tested in the 
chronic infection models to determine if therapeutic effects are still observed with the changes in 
immune response that eventually occur during a sustained infection. Effects of long-term usage 
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should also be considered if these compounds will be used to as an ongoing treatment in cases of 
chronic infection.  
While the present work has focused the application of these cationic glucocorticoids for 
enhancing gene therapies of CF, the therapeutic potential of these compounds be extended to 
other applications as well. In particular, the dual anti-inflammatory and antimicrobial 
functionality are particularly suited for treating infections associated with elevated tissue damage. 
Examples include bacterial keratits (bacterial infections of the cornea) and otitis externa 
(inflammation or infection of the ear canal).  Such conditions benefit from combined 
antibiotic/steroid treatment over treatment that only utilized one or the other  [54,55]. The 
cationic glucocorticoids presented here could provide a useful alternative to current methods by 
eliminating the need for a dual-compound therapy for these conditions.  
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Appendix A: Mass spectrometry data for FS, F2S, BuS, Bu2S, BeS, and 
Be2S 
 
Figure A1: Structures of FS and F2S with mass spectrometry data showing multiple ionizations. 
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Figure A2: Structures of BuS and Bu2S with mass spectrometry data showing multiple ionizations. 
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Figure A3: Structures of BeS and Be2S with mass spectrometry data showing multiple ionizations. 
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Appendix B: 
1
H NMR Data for FS, F2S, BuS, Bu2S, BeS, and Be2S 
 
Figure B1: 1H NMR spectrum of FS 
Flumethasone Spermine, FS, N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2-
((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide 
1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.19 (s, 1H), 8.16 (s, 0H), 7.30 (dd, J = 10.2, 1.5 Hz, 1H), 6.30 (dd, J = 
10.1, 1.9 Hz, 1H), 6.12 (s, 1H), 5.69 (ddd, J = 11.4, 6.6, 2.0 Hz, 1H), 5.59 (ddd, J = 11.5, 6.7, 2.0 Hz, 1H), 5.46 (dd, J = 
4.7, 1.6 Hz, 1H), 5.11 (s, 1H), 4.17 (td, J = 6.4, 3.1 Hz, 1H), 3.83 (d, J = 16.6 Hz, 1H), 3.44 (d, J = 16.6 Hz, 1H), 3.28 
(s, 1H), 3.03 – 2.87 (m, 10H), 2.57 (td, J = 7.1, 2.4 Hz, 2H), 2.48 (dd, J = 19.8, 6.3 Hz, 2H), 2.21 (tt, J = 11.2, 4.3 Hz, 
3H), 1.90 (dp, J = 14.9, 7.6 Hz, 6H), 1.73 – 1.62 (m, 5H), 1.55 – 1.47 (m, 1H), 1.50 (s, 3H), 1.51 – 1.41 (m, 1H), 1.12 
(ddd, J = 12.2, 8.1, 4.2 Hz, 1H), 0.89 (s, 3H), 0.81 (d, J = 7.3 Hz, 3H). 
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Figure B2: 1H NMR spectrum of F2S  
Disubstituted flumethasone spermine, F2S, 4-((2-((6R,8R,9S,10R,11R,13R,14R,16S,17S)-6,9-difluoro-11,17-
dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-
yl)-2-oxoethyl)thio)-N-(1-((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-
oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17-
triazaicosan-20-yl)butanimidamide 1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.10 (s, 1H), 8.19 (s, 0H), 7.29 (dd, J 
= 10.2, 1.5 Hz, 1H), 6.30 (dd, J = 10.2, 1.9 Hz, 1H), 5.63 (dddd, J = 48.7, 11.4, 6.7, 1.9 Hz, 1H), 5.37 (s, 1H), 5.01 (s, 
1H), 4.22 – 4.15 (m, 1H), 3.82 (d, J = 16.5 Hz, 1H), 3.44 (d, J = 16.5 Hz, 1H), 3.30 (t, J = 7.0 Hz, 1H), 2.84 (dd, J = 
16.5, 9.0 Hz, 2H), 2.59 (td, J = 7.1, 2.9 Hz, 1H), 2.58 – 2.41 (m, 1H), 2.23 (ddt, J = 13.8, 7.8, 5.6 Hz, 2H), 1.87 (dp, J = 
28.8, 7.4 Hz, 2H), 1.69 (q, J = 12.5, 11.8 Hz, 1H), 1.65 – 1.58 (m, 1H), 1.52 (s, 2H), 1.55 – 1.45 (m, 1H), 1.14 (ddd, J = 
12.1, 8.1, 4.1 Hz, 1H), 0.91 (s, 2H), 0.83 (d, J = 7.2 Hz, 2H). 
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Figure B3: 1H NMR spectrum of BuS  
Budesonide Spermine, BuS N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2-
((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR) -7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl-
1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-
oxoethyl)thio)butanimidamide 1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.13 (s, 1H), 8.55 (s, 4H), 7.32 (dd, J = 
10.1, 3.1 Hz, 1H), 6.17 (d, J = 10.0 Hz, 1H), 5.93 (s, 1H), 4.81 – 4.72 (m, 1H), 4.30 (d, J = 9.7 Hz, 1H), 3.70 (dd, J = 
16.1, 4.6 Hz, 1H), 3.42 (dd, J = 16.1, 8.1 Hz, 1H), 2.90 (dt, J = 24.2, 7.7 Hz, 6H), 2.57 (t, J = 6.7 Hz, 1H), 2.30 (d, J = 
13.4 Hz, 1H), 2.00 (dt, J = 19.1, 8.9 Hz, 1H), 1.83 (ddt, J = 32.5, 24.6, 10.5 Hz, 5H), 1.65 – 1.52 (m, 4H), 1.53 (d, J = 
7.7 Hz, 1H), 1.38 (s, 2H), 1.32 (ddd, J = 32.3, 16.0, 8.5 Hz, 2H), 1.21 (s, 0H), 1.11 (qd, J = 12.4, 4.6 Hz, 0H), 1.03 (s, 
0H), 1.03 – 0.91 (m, 1H), 0.85 (dt, J = 15.7, 7.9 Hz, 4H). 
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Figure B4: 1H NMR spectrum of Bu2S  
Disubstituted Budesonide Spermine, Bu2S 4-((2-((6aR,6bS,7S,8aS,8bS,10(R,S),11aR,12aS,12bS)-7-hydroxy-6a,8a-
dimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-
d][1,3]dioxol-8b-yl)-2-oxoethyl)thio)-N-(1-((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR)-7-hydroxy-6a,8a-
dimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-
d][1,3]dioxol-8b-yl)-7-imino-1-oxo-3-thia-8,12,17-triazaicosan-20-yl)butanimidamide 1H NMR (500 MHz, DMSO-d6 
with TMS) δ 9.17 (s, 0H), 8.82 (s, 1H), 8.14 (s, 0H), 7.32 (dd, J = 10.1, 3.0 Hz, 1H), 6.17 (dd, J = 10.0, 2.3 Hz, 1H), 
5.93 (s, 1H), 5.19 (t, J = 4.9 Hz, 0H), 5.05 (d, J = 7.4 Hz, 0H), 4.81 – 4.73 (m, 1H), 4.64 (t, J = 4.4 Hz, 0H), 4.30 (dp, J 
= 9.7, 3.3 Hz, 1H), 3.70 (dd, J = 16.1, 4.9 Hz, 1H), 3.42 (dd, J = 16.1, 7.7 Hz, 1H), 3.29 (t, J = 6.8 Hz, 7H), 2.94 (p, J = 
6.6, 5.5 Hz, 2H), 2.59 (q, J = 6.8 Hz, 1H), 2.51 – 2.45 (m, 1H), 2.34 – 2.27 (m, 1H), 2.11 – 1.95 (m, 1H), 1.87 (td, J = 
16.7, 16.1, 10.1 Hz, 3H), 1.84 – 1.59 (m, 1H), 1.65 (s, 1H), 1.62 – 1.53 (m, 1H), 1.56 – 1.50 (m, 1H), 1.46 – 1.23 (m, 
3H), 1.20 – 1.02 (m, 0H), 0.98 (ddt, J = 25.2, 11.1, 5.4 Hz, 1H), 0.85 (dt, J = 15.5, 7.6 Hz, 3H). 
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Figure B5: 1H NMR spectrum of BeS  
Beclomethasone Spermine, BeS  N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2-
((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide 1H 
NMR (500 MHz, DMSO-d6 with TMS) δ 9.20 (s, 1H), 8.64 (s, 6H), 7.32 (d, J = 10.1 Hz, 1H), 6.24 (dd, J = 10.1, 1.9 
Hz, 1H), 6.00 (d, J = 1.9 Hz, 1H), 5.48 (d, J = 4.6 Hz, 1H), 5.36 (s, 1H), 4.35 (q, J = 3.4 Hz, 1H), 3.77 (d, J = 16.5 Hz, 
1H), 3.55 (d, J = 16.5 Hz, 1H), 3.29 (t, J = 6.9 Hz, 1H), 2.97 (ddd, J = 10.6, 6.9, 2.7 Hz, 2H), 2.93 (s, 3H), 2.93 – 2.86 
(m, 2H), 2.66 (td, J = 11.6, 11.1, 4.2 Hz, 1H), 2.54 (d, J = 7.2 Hz, 1H), 2.52 – 2.42 (m, 2H), 2.36 (dd, J = 13.8, 4.9 Hz, 
1H), 2.27 – 2.11 (m, 1H), 1.95 – 1.78 (m, 5H), 1.64 (d, J = 9.2 Hz, 4H), 1.60 – 1.48 (m, 1H), 1.35 (dd, J = 13.9, 2.4 Hz, 
1H), 1.14 – 1.02 (m, 2H), 1.00 (s, 2H). 
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Figure B6: 1H NMR spectrum of Be2S  
Disubstituted Beclomethasone Spermine, Be2S 4-((2-((8R,9S,11R,13R,14R,16R,17S)-9-chloro-11,17-dihydroxy-
10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-
oxoethyl)thio)-N-(1-((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17-
triazaicosan-20-yl)butanimidamide 1H NMR (500 MHz, DMSO-d6 with TMS) δ 9.17 (s, 1H), 8.30 (s, 0H), 7.30 (d, J = 
10.2 Hz, 1H), 6.22 (dd, J = 10.1, 1.9 Hz, 1H), 5.98 (d, J = 1.8 Hz, 1H), 5.52 (s, 1H), 5.41 (s, 1H), 4.33 (d, J = 3.1 Hz, 
1H), 3.76 (d, J = 16.5 Hz, 1H), 3.54 (d, J = 16.5 Hz, 1H), 3.27 (t, J = 6.9 Hz, 1H), 2.82 (dt, J = 14.9, 6.8 Hz, 3H), 2.64 
(td, J = 11.2, 4.1 Hz, 1H), 2.56 – 2.40 (m, 2H), 2.38 – 2.30 (m, 1H), 2.25 – 2.08 (m, 1H), 1.85 (dddq, J = 25.5, 19.6, 
11.2, 5.5, 4.8 Hz, 4H), 1.60 (s, 3H), 1.51 (td, J = 12.9, 12.5, 5.2 Hz, 1H), 1.32 (dd, J = 13.8, 2.5 Hz, 1H), 1.11 – 0.99 
(m, 2H), 0.97 (s, 2H). 
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Appendix C: 
13
C NMR Data for FS, F2S, BuS, Bu2S, BeS, and Be2S 
 
 
Figure C1: 13C NMR spectrum of FS 
Flumethasone Spermine, FS, N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2-
((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo 
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide 
13C NMR (126 MHz, DMSO-d6 with TMS) δ 206.96 (16), 184.38 (1), 166.98 (30), 163.02 (6), 162.91 (6), 151.86 (3), 
129.02 (2), 119.42 (5), 119.32(5), 100.75 (24), 99.35 (24), 90.87 (14), 87.53 (7), 86.10 (7), 70.4 4(22), 70.16 (22), 
48.14 (26), 48.12 (26), 47.97 (26), 47.94 (26), 47.52 (19), 46.15 (41, 44), 44.19 (46), 43.90 (39), 42.92 (10), 39.05 (12), 
38.43 (18), 36.19 (37), 35.81 (31), 34.69 (11), 33.89 (21), 33.75 (21), 32.23 (8), 32.14(8), 32.08 (8), 31.99 (8), 31.69 
(9), 31.61 (9), 30.41 (33), 26.34 (47), 24.02 (38), 23.79 (32), 22.76 (27), 22.73 (42, 43), 22.65 (27), 16.67 (20), 15.12 
(13). 
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Figure C2: 13C NMR spectrum of F2S 
Disubstituted-flumethasone spermine, F2S, 4-((2-((6R,8R,9S,10R,11R,13R,14R,16S,17S)-6,9-difluoro-11,17-
dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-
yl)-2-oxoethyl)thio)-N-(1-((6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-
oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17-
triazaicosan-20-yl)butanimidamide 13C NMR (126 MHz, DMSO-d6 with TMS) δ 206.94 (16, 64), 184.37 (1, 49), 
166.96 (30, 78), 163.79 (6,54), 163.00 (6,54), 162.89 (6,54), 151.83 (3, 51), 129.03 (2, 50), 119.42 (5,53), 119.32 
(5,53), 100.75 (24,72), 99.34 (24,72), 90.87 (14, 62), 87.52 (7,55), 86.09 (7,55), 70.45 (22,70), 70.16 (22,70), 48.14 
(26,74), 48.11 (26,74), 47.96 (26,74), 47.93 (26,74), 47.53 (41,44), 46.95 (19,67), 44.61 (39, 46), 42.92 (10, 58), 39.60 
(37, 48), 39.43 (12,60), 38.42 (18, 66), 35.82 (31, 79), 34.69 (11, 59), 33.89 (21,69), 33.74 (21,69), 32.23 (8,56), 32.14 
(8,56), 32.08 (8,56), 31.99 (8,56), 31.68 (9,57), 31.61 (9,57), 30.39 (33, 81), 26.35 (38, 47), 24.98 (32, 80), 24.05 (42, 
43), 22.76 (27,75), 22.71 (27,75), 16.67 (20, 68), 15.12 (13, 61). 
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Figure C3: 13C NMR spectrum of BuS 
Budesonide Spermine, BuS N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2-
((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR)-7-hydroxy-6a,8a-dimethyl-4-oxo-10-propyl-
1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-
oxoethyl)thio)butanimidamide 13C NMR (126 MHz, DMSO-d6 with TMS) δ 205.38 (22), 203.73 (22), 185.05 (2), 
170.13 (4), 170.04 (4), 166.89 (46), 163.10 (46), 156.33 (6), 127.09 (1), 127.06 (1), 121.67 (3), 121.61 (3), 107.10 (27), 
103.46 (27), 98.75 (20), 98.17 (20), 81.86 (18), 80.84 (18), 68.07 (16), 68.02 (16), 55.00 (12), 52.04 (13), 49.35 (13), 
46.36 (14), 45.40 (14), 44.35 (37, 40), 44.11 (5), 43.60 (42), 40.18 (15), 39.93 (44), 39.59 (23), 37.57 (47), 37.29 
(37.29), 36.41 (28), 36.34 (28), 34.49 (28), 33.81 (10), 33.44 (10), 32.92 (17), 32.19 (17), 31.63 (8), 31.11 (8), 30.54 
(49), 30.49 (49), 29.89 (11), 26.16 (43), 26.11 (43), 24.37 (48), 24.14 (48), 23.14 (38, 39), 20.72 (9), 20.68 (9), 17.30 
(21), 17.06 (21), 16.78 (29), 16.37 (29), 13.84 (30), 13.77 (30). 
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Figure C4: 13C NMR spectrum of Bu2S 
Disubstituted Budesonide Spermine, Bu2S 4-((2-((6aR,6bS,7S,8aS,8bS,10(R,S),11aR,12aS,12bS)-7-hydroxy-6a,8a-
dimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-
d][1,3]dioxol-8b-yl)-2-oxoethyl)thio)-N-(1-((6aS,6bR,7R,8aR,8bR,10(R,S),11aS,12aR,12bR)-7-hydroxy-6a,8a-
dimethyl-4-oxo-10-propyl-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-
d][1,3]dioxol-8b-yl)-7-imino-1-oxo-3-thia-8,12,17-triazaicosan-20-yl)butanimidamide 13C NMR (126 MHz, DMSO-d6 
with TMS) δ 205.35 (22,78), 203.70 (22,78), 185.02 (2,58), 170.07 (4,60), 169.98 (4,60), 166.83 (46,52), 166.76 
(46,52), 162.87 (46,52), 156.32 (6,62), 156.28 (6,62), 127.09 (1,57), 127.05 (1,57), 121.67 (3,59), 121.61 (3,59), 
107.10 (27,83), 103.46 (27,83), 98.75 (20,76), 98.17 (20,76), 81.86 (18,74), 80.83 (18,74), 68.08 (16,72), 68.02 
(16,72), 67.96 (16,72), 67.90 (16,72), 54.99 (12,68), 54.96 (12,68), 52.05 (13,69), 49.35 (13,69), 46.36 (14,70), 46.08 
(14,70), 45.39 (37,40), 44.12 (5, 61), 43.59 (35,42), 40.10 (15,71), 39.93 (33,44), 39.59 (23,79), 37.55 (47,53), 37.28 
(47,53), 36.42 (28,84), 34.50 (28,84), 33.80 (10,66), 33.45 (10,66), 32.91 (17,73), 32.19 (17,73), 31.57 (8,64), 31.12 
(8,64), 30.55 (49,55), 30.49 (49,55), 29.90 (11,67), 26.14 (34,43), 26.08 (34,43), 23.97 (48,54), 22.70 (38,39), 20.71 
(9,65), 20.68 (9,65), 17.29 (21,77), 17.05 (21,77), 16.78 (29,85), 16.38 (29,85), 13.83 (30,86), 13.76 (30,86). 
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Figure C5: 13C NMR spectrum of BeS 
Beclomethasone Spermine, BeS  N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)-4-((2-
((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo 
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)thio)butanimidamide 
13C NMR (126 MHz, DMSO-d6 with TMS) δ 207.78 (20), 185.34 (3), 167.04 (5), 166.90 (5), 163.70 (43), 152.91 (1), 
128.65 (2), 124.08 (4), 88.44 (19), 85.70 (11), 74.20 (15), 49.77 (6), 48.59 (13), 46.46 (33, 36), 46.31 (12), 44.30 (31), 
44.03 (38), 42.91 (17), 40.96 (40), 40.11, 39.78 (44), 36.30 (14), 35.94 (29), 34.18 (10), 33.96 (16), 31.77 (46), 30.25 
(21), 29.98 (8), 27.63 (9), 26.46 (39), 24.44 (23), 24.24 (45), 24.03 (30), 23.00 (34,35), 22.93 (34,35), 20.17 (25), 17.81 
(26). 
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Figure C6: 13C NMR spectrum of Be2S 
Disubstituted Beclomethasone Spermine, Be2S 4-((2-((8R,9S,11R,13R,14R,16R,17S)-9-chloro-11,17-dihydroxy-
10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-
oxoethyl)thio)-N-(1-((8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-
6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-7-imino-1-oxo-3-thia-8,12,17-
triazaicosan-20-yl)butanimidamide 13C NMR (126 MHz, DMSO- d6 with TMS) δ 207.79 (20, 73), 185.33 (3, 56), 
167.02 (5,58), 166.88 (5,58), 165.14 (43, 49), 152.91 (1, 54), 128.65 (2,55), 124.08 (4, 57), 88.42 (19, 72), 85.69 
(11,64), 74.20 (15, 68), 49.77 (6, 59), 48.57 (13,66), 46.79 (33, 36), 46.47 (12, 65), 44.53 (31, 38), 42.91 (17, 70), 
40.97 (29, 40), 39.78 (44, 50), 35.93 (14, 67), 34.18 (16, 69), 33.96 (10, 63), 31.75 (46, 52), 30.22 (21, 74), 29.98 (8, 
61), 27.63 (9, 62), 26.48 (30, 39), 24.89 (45,51), 24.44 (23, 76), 23.87 (34, 35), 20.17 (25, 78), 17.81 (26, 79). 
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